2021 AAN Annual Meeting Networking and Engagement Program

April 17 – April 22

Networking and Engagement

AAN Excellence— Delivered Unconventionally

NOW IS THE TIME TO STEP INTO THEIR SHOES AND START SEEING THINGS FROM ANOTHER PERSPECTIVE. STEPINTOXCOPRI.com

©2021 SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd. PM-US-XCOP-0151 03/21

CONTENTS Introduction Ways to Engage with Your Colleagues Registration Exclusive Virtual Gold Programs by Topic

3 4 6

Networking & Programming Meeting-at-a-glance Evening Entertainment Networking/Entertainment Hub Alumni Reunions Plenary Sessions AAN Showcase Awards Theater Experiential Learning Areas

10 17 19 21 23 26 28 54

Navigating the Meeting Virtual Platform Guide Mobile App Guide

61 64

Prepare for your virtual Annual Meeting experience: 1. Register at AAN.com/21AM 2. Block your calendar for April 17-22 or save time for your can't-miss sessions throughout the week. Use AAN.com/2021Program for downloadable calendar reminders.

3. Download the AAN Conferences mobile app to start planning your schedule.

4. Share what you’re excited about using #AANAM Remember: Your registration includes access to sessions through May 23, 2021.

Conference Guidelines Participation in a virtual AAN meeting is subject to the AAN’s Privacy Policy. All individuals engaged in any virtual meeting are subject to the AAN.com Code of Conduct, unless otherwise specifically noted. Use of the website and virtual program site(s) is subject to AAN’s Terms of Use. These conference policies are subject to change without notice, at AAN’s discretion. Any changes will be reflected on AAN.com/conferences-community/conference-guidelines.

The information and preliminary program details presented in this booklet are accurate as of March 19, 2021, and subject to change. Schedule is listed in Eastern Time. Please visit AAN.com/21AM for the most up-to-date information and more programming details.

AAN.com/21AM

1

AAN EXCELLENCE—DELIVERED UNCONVENTIONALLY

”

I am excited for a fun and accessible Annual Meeting program. As a parent to young children, I appreciate the opportunity to experience the excellent content of the #AANAM without leaving home— and the flexibility of a virtual platform that allows for greater live attendance and networking.

In-person networking can be random, but with the topic-specific sessions in this year’s Networking/Entertainment Hub, I will be more likely to make contact with colleagues with similar interests. I’m also looking forward to the opportunity to video chat on topic-specific chat channels and see which of my colleagues and friends from around the world are at the meeting using the World Map.

”

In addition to the ability to easily connect with colleagues in a meaningful and effective way, I am also looking forward to the fun nightly events! Jim Gaffigan will provide clean, smart fun and I intend to participate in the culinary experiences, too!

There are so many reasons why this year is the year to attend the Annual Meeting, and I encourage you to peruse the following pages for more detail on the many convenient ways to network and engage this April. I look forward to catching up with you there!

Teri Schreiner, MD, MPH, FAAN Chair, Annual Meeting Networking and Engagement Work Group Member, Meeting Management Committee 2 2021 AAN Annual Meeting

Top Ways to Engage with Your Colleagues at the Annual Meeting 1

Visit the Networking/Entertainment Hub (see page 19) for meaningful networking opportunities throughout the Annual Meeting: 15+ networking sessions, chat channels, and a leaderboard. Remember to smile for the camera at the photo booth, share your favorite moments on social media, and see who is at the meeting on the World Map.

2

Over 200 hours of programming that includes live Q&A components—attend at the scheduled session time to join the conversation and ask your most pressing questions.

3

Four evenings of entertainment (see page 17).

From comedy and improv, to cooking demos and a mixologist, we have something for everyone.

Culminating with the live AAN Talent Show where you can view an evening of performances from your talented colleagues and vote on your favorite, these are nights to remember.

4

Explore the virtual platform for even more ways to engage (and earn points on the leaderboard while visiting different locations). Experiential Learning Areas (page 54), the AAN Showcase (page 26), Awards Theater (page 28), and Alumni Reunions (page 21) are great ways to catch up with friends, meet new people, and get the most from your Annual Meeting experience.

AAN.com/21AM

3

REGISTRATION There are two ways to experience the Annual Meeting.

Virtual Registration Your Virtual Registration for the Annual Meeting includes access to live streaming and recorded sessions for 30 days after the conference. This exceptional value includes:

All the CME You Need for the Year 90+ expert-led education courses

Access to program syllabi and slides

2,000+ scientific abstracts presented in multiple formats

200+ hours of programming that includes live Q&A components— attend at the scheduled session time to join the conversation

7 Plenary Sessions featuring leaders in neurology Experiential Learning Area Talks

Networking Opportunities 15+ scheduled networking sessions

Evening fun and entertainment

AAN Chat Channels in the areas of: telemedicine, leadership, equity and inclusion, and more

Create your own private one-onone or small group chat channel on the subject of your choice and invite your colleagues to participate

Access to AAN and Industry Resources AAN Showcase (Learn more on page 26) Interactive virtual exhibit hall with 90+ exhibiting organizations where you can learn about the latest innovations in neurology and patient care 32 Industry Therapeutic Updates providing the latest scientific updates about current and pipeline therapies presented by leading industry partners

Virtual Gold Registration

Best Value

Upgrade to Virtual Gold Registration for the best value with extended access and additional courses through March 31, 2022, with Annual Meeting On Demand. In addition to all of the benefits of Virtual Registration, you’ll retain access to all meeting syllabi and virtual session recordings, CME, and receive exclusive access to more than 25 bonus sessions and presentations to round out this comprehensive digital reference library accessible anytime, anywhere. Learn more on page 6.

4 2021 AAN Annual Meeting

Register now Online

AAN.com/21AM

Phone

(800) 676-4226 (US/Canada) (415) 979-2283 (International)

Standard Registration Rates

Best Value

Member Type

Virtual

Virtual Gold

Student Member

$0

$79

Honorary or Senior Member

$0

$239

Junior or Intern Member

$250

$329

Non-physician Member*

$445

$614

Neurologist or Physician Affiliate Member

$630

$869

Nonmember

$900

$1,279

*Non-physician member includes Business Administrator, Researcher, and Advanced Practice Provider member types.

All sales for online programs including virtual conferences are final, nonrefundable, and nontransferable. Registration includes access to programs and materials on demand after the end of the conference.

Become an AAN member today for registration discounts. Visit AAN.com/membership.

Protect yourself from fraudulent companies.

Convention Management Resources (CMR) is the official registration partner of the AAN. Kenes Group is the official virtual platform provider of the 2021 Annual Meeting.

AAN.com/21AM

5

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

Upgrade to Virtual Gold Registration for the best value with Annual Meeting On Demand.

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

You’ll get exclusive extended access through March 31, 2022, to all programming available through standard registration, the ability to claim additional CME, plus access to the below bonus sessions. The following sessions offer 1 CME each.

The program is subject to change. Visit AAN.com/2021Program for the most upto-date information and more detail on each program.

Member Type

Upgrade Cost Post-meeting Cost

(With Registration)

Student / Junior / Intern

$79

$150

APP / Business Administrator / Researcher

$169

$375

Neurologist / Physician Affiliate / Senior / Honorary

$239

$525

Nonmember

$379

$750

Aging, Dementia, Cognitive, and Behavioral Neurology

Epilepsy/Clinical Neurophysiology (EEG)

Behavioral Neurology

Clinical Epilepsy 2: Advanced

Autoimmune Neurology

Clinical EEG 2

Neuro-rheumatology: Neurologic Manifestations of Systemic Inflammatory and Autoimmune Disease

General Neurology

Cerebrovascular Disease and Interventional Neurology

Neurologic Complications of Medical Disease

Cerebrovascular Disease Prevention Maximizing Quality of Life in Serious Neurologic Illnesses Telestroke

Child Neurology and Developmental Neurology Neurogenetics Treatment of Pediatric Multiple Sclerosis in the Current Era Update in Child Neurology 2 6 2021 AAN Annual Meeting

Neurogenetics

Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Mitochondrial Disorders in Neurology Good Neurology in Challenging Conditions: Lessons from Military Neurology Clinical Pearls: Learning from Complex Cases: Simple Lessons that Apply to Everyday Problems

Headache

Neuro-ophthalmology/Neuro-otology

Hot Topics in Headaches and Related Disorders

Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings

Infectious Disease

Ophthalmic Imaging for Neurologists: OCT and Funduscopy in the 21st Century

Emerging Infectious Diseases of the Nervous System

Deep Brain Stimulation Maximizing Quality of Life in Serious Neurologic Illnesses Tourette Syndrome: Assessment and Management

MS and CNS Inflammatory Disease Treatment of Pediatric Multiple Sclerosis in the Current Era Neuromyelitis Optica Spectrum Disorders

Neuro Trauma, Critical Care, and Sports Neurology Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

Spinal Cord Rehabilitation

Pain and Palliative Care Maximizing Quality of Life in Serious Neurologic Illnesses

Practice, Policy, and Ethics Burnout and Resilience: Strategies and Evidence for Enhancing Well-being Maximizing Quality of Life in Serious Neurologic Illnesses

Sleep Sleep for the Practicing Neurologist: Disordered Sleep in Common Neurologic Diseases

Neuromuscular and Clinical Neurophysiology (EMG) Clinical EMG Small Fiber Neuropathies Maximizing Quality of Life in Serious Neurologic Illnesses

Neuro-oncology Neurologic Consultations in Cancer Patients

AAN.com/21AM

7

EXCLUSIVE VIRTUAL GOLD PROGRAMS BY TOPIC

Movement Disorders

Neuro-rehabilitation

You are cordially invited to a Virtual Industry Therapeutic Update from Janssen Neuroscience

New Treatment Option in Multiple Sclerosis: Addressing Unmet Needs MONDAY, APRIL 19, 2021 • 7:00 pm – 8:00 pm (et)

Daniel Kantor, MD

PROGRAM DESCRIPTION

President, Kantor Neurology, LLC, Coconut Creek, Florida Clinical Affiliate Associate Professor of Neurology, Florida Atlantic University, Boca Raton, Florida

This presentation will review the disease burden of multiple sclerosis (MS) and share key safety and efficacy data from a landmark oral-to-oral clinical trial.

Speaker has been compensated.

This event is not part of the AAN Annual Meeting official programming and no CME will be given for attendance. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers are compensated and present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc., educational program using your preferred method of communication as indicated by you. This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

Supported by Janssen Pharmaceuticals, Inc.

© Janssen Pharmaceuticals, Inc. 2021 3/21 cp-211190v1

CONNECTING IN

SPECTACULAR

WAYS

The power of connection is more evident than ever before. The 2021 Annual Meeting will be packed with innovative virtual opportunities for socializing, networking, and entertainment, including nightly events and networking lounges available three times each day on different topics to engage in casual conversation.

Evening Events 7:00 p.m.–8:00 p.m. ET

Saturday, April 17: Comedy Night with Jim Gaffigan

Sunday, April 18: Fun & Games

Tuesday, April 20: AAN Talent Show

Monday, April 19: Culinary Experiences

See page 17 for more details

MEETING-AT-A-GLANCE

SAT April 17 8:00 a.m. ET

9:00 a.m. ET

Posters Networking Session

10:00 a.m. ET

C1 8:00 a.m.–2:00 p.m. ET 11:00 a.m. ET

C2 8:00 a.m.–5:00 p.m. ET

C3–C5 12:00 p.m. ET

9:00 a.m.–10:00 a.m. ET

Exhibit Hall

Experiential Learning Areas Frontiers in Neuroscience Plenary Session Live fireside chat with speakers: 12:00 p.m.–1:00 p.m. ET

The following pages provide a high-level look at when the various types of programming will be offered. Programming is in Eastern Time. For the best experience, tune in during the scheduled time to participate in Q&As, networking, and other interactive components of the conference.

The program schedule is subject to change; visit AAN.com/2021Program for the complete program search and latest information, and to add specific programs to your calendar.

C6–C8 12:00 p.m.–1:00 p.m. ET

1:00 p.m. ET

C9–C11 2:00 p.m.–3:00 p.m. ET

C12 2:00 p.m. ET

2:00 p.m.–5:00 p.m. ET

C13–C17 4:00 p.m.–5:00 p.m. ET

3:00 p.m. ET

4:00 p.m. ET

5:00 p.m. ET

Industry Therapeutic Updates

S1–S3 Live Q&As: 2:16 p.m.–2:24 p.m.

ET and 2:48 p.m.–3:00 p.m. ET

Neuroscience in the Clinic

Networking Session AAN Business Meeting Hot Topics: Neuro-COVID Plenary Session

6:00 p.m. ET

7:00 p.m. ET

Networking Session

Comedy Night with Jim Gaffigan

8:00 p.m. ET

10 2021 AAN Annual Meeting

S4–S6 Live Q&As: 4:16 p.m.–4:24 p.m.

ET and 4:48 p.m.–5:00 p.m. ET

Experiential Learning Areas

C = Course

= Experiential Learning Area

S = Scientific Session

SUN April 18 Posters

8:00 a.m. ET

C18–C22

Exhibit Hall

Networking Session

Industry Therapeutic Updates

9:00 a.m. ET

Experiential Learning Areas 10:00 a.m. ET

Presidential Plenary Session Live fireside chat with speakers: 1:00 p.m.–2:00 p.m. ET

11:00 a.m. ET

12:00 p.m. ET

Industry Therapeutic Updates

Networking Session S7–S9 Live Q&As: 2:16 p.m.–2:24 p.m.

ET and 2:48 p.m.–3:00 p.m. ET

C28

4:00 p.m.–5:00 p.m. ET

C34–C38

Live Q&As: 4:16 p.m.–4:24 p.m.

ET and 4:48 p.m.–5:00 p.m. ET

2:00 p.m. ET

2:00 p.m.–3:00 p.m. ET

C29–C33

S10–S12

Experiential Learning Areas

C23–C27

2:00 p.m.–6:30 p.m. ET

Networking Session

1:00 p.m. ET

6:00 p.m.–7:00 p.m. ET

Emerging Science Session 3:00 p.m.–3:45 p.m. ET: Blitz Presentations 3:45 p.m.–4:30 p.m. ET: Q&A Breakouts

Neuroscience in the Clinic

3:00 p.m. ET

4:00 p.m. ET

5:00 p.m. ET

6:00 p.m. ET

Fun and Games

Industry Therapeutic Updates

7:00 p.m. ET

8:00 p.m. ET

AAN.com/21AM

11

MEETING-AT-A-GLANCE MON April 19 8:00 a.m. ET

9:00 a.m. ET

Posters

C39–C42

Exhibit Hall

Networking Session

Industry Therapeutic Updates

10:00 a.m. ET

Experiential Learning Areas

Contemporary Clinical Issues Plenary Session

11:00 a.m. ET

Live fireside chat with speakers: 12:30 p.m.–1:30 p.m. ET

12:00 p.m. ET

1:00 p.m. ET

2:00 p.m. ET

Networking Session

Industry Therapeutic Updates

S13–S15 Live Q&As: 2:16 p.m.–2:24 p.m.

ET and 2:48 p.m.–3:00 p.m. ET

3:00 p.m. ET

4:00 p.m. ET

Networking Session S16–S18 Live Q&As: 4:16 p.m.–4:24 p.m.

ET and 4:48 p.m.–5:00 p.m. ET

5:00 p.m. ET

C43

(Health Care Equity Symposium) 1:00 p.m.–3:00 p.m. ET

C44–C47 2:00 p.m.–3:00 p.m. ET

C48 2:00 p.m.–6:00 p.m. ET

C49 2:00 p.m.–6:30 p.m. ET

C50–C53 4:00 p.m.–5:00 p.m. ET

C54–C58 6:00 p.m.–7:00 p.m. ET

6:00 p.m. ET

7:00 p.m. ET

Culinary Experiences

8:00 p.m. ET

12 2021 AAN Annual Meeting

Industry Therapeutic Updates

Experiential Learning Areas Neuroscience in the Clinic

C = Course

= Experiential Learning Area

S = Scientific Session

TUE April 20 Posters

8:00 a.m. ET

C59–C62

Exhibit Hall

Networking Session

Industry Therapeutic Updates

9:00 a.m. ET

Experiential Learning Areas 10:00 a.m. ET

Clinical Trials Plenary Session Live fireside chat with speakers: 12:30 p.m.–1:30 p.m. ET

11:00 a.m. ET

12:00 p.m. ET

Industry Therapeutic Updates

Networking Session S19–S22

Inspirational Talk with Alison Levine

2:00 p.m. ET

C63–C67

Live Q&As: 2:16 p.m.–2:24 p.m.

ET and 2:48 p.m.–3:00 p.m. ET

2:00 p.m.–3:00 p.m. ET

C68–C71 4:00 p.m.–5:00 p.m. ET

Networking Session

1:00 p.m. ET

Experiential Learning Areas

3:00 p.m. ET

C72–C76 6:00 p.m.–7:00 p.m. ET

S23–S25

4:00 p.m. ET

Live Q&As: 4:16 p.m.–4:24 p.m.

ET and 4:48 p.m.–5:00 p.m. ET

Neuroscience in the Clinic

5:00 p.m. ET

6:00 p.m. ET

AAN Talent Show

Industry Therapeutic Updates

7:00 p.m. ET

8:00 p.m. ET

AAN.com/21AM

13

MEETING-AT-A-GLANCE

WED April 21 8:00 a.m. ET

9:00 a.m. ET

Posters

C77–C80

Exhibit Hall

Networking Session

Industry Therapeutic Updates

10:00 a.m. ET

Experiential Learning Areas

Controversies in Neurology Plenary Session

11:00 a.m. ET

Live fireside chat with speakers: 12:30 p.m.–1:30 p.m. ET 12:00 p.m. ET

1:00 p.m. ET

2:00 p.m. ET

Networking Session

Industry Therapeutic Updates

S26–S28 Live Q&As: 2:16 p.m.–2:24 p.m.

ET and 2:48 p.m.–3:00 p.m. ET

3:00 p.m. ET

4:00 p.m. ET

Experiential Learning Areas

Neuroscience in the Clinic

C81–C84 2:00 p.m.–3:00 p.m. ET

C85–C88 4:00 p.m.–5:00 p.m. ET

Networking Session

C89–C92 6:00 p.m.–7:00 p.m. ET

S29–S32 Live Q&As: 4:16 p.m.–4:24 p.m.

ET and 4:48 p.m.–5:00 p.m. ET

5:00 p.m. ET

Neuroscience in the Clinic

6:00 p.m. ET

7:00 p.m. ET

8:00 p.m. ET

14 2021 AAN Annual Meeting

Commitment to Cures Gala 8:00 p.m.–9:00 p.m. ET

C = Course

= Experiential Learning Area

S = Scientific Session

THU April 22 Prepare for your 8:00 a.m. ET virtual Annual Meeting experience: Networking Session

9:00 a.m. ET

Experiential Learning Areas

Neurology Year in Review Plenary Session

1. Register at AAN.com/21AM

2. Block your calendar for April 17-22 or save time for your can't-miss sessions 10:00 a.m. ET throughout the week. Use AAN.com/2021Program for downloadable calendar 11:00 a.m. ET reminders.

3. Download the AAN Conferences mobile app to start planning your schedule.

12:00 p.m. ET 4. Share what you’re excited about using #AANAM

Experiential Learning Areas

Remember: Your registration includes access to sessions 1:00 p.m. ET through May 23, 2021.

2:00 p.m. ET

3:00 p.m. ET

4:00 p.m. ET

5:00 p.m. ET

Emerging Science The Emerging Science program highlights the most current research being done in the field of neurology. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 2020 abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. These previously unpublished abstracts contain timely, significant, and innovative content. Abstract titles are now available at AAN.com and you can hear authors' presentations and join them in breakout rooms for further discussion and questions on Sunday, April 18, from 3:00 p.m.-4:30 p.m. ET. AAN.com/21AM

6:00 p.m. ET

7:00 p.m. ET

8:00 p.m. ET

15

A “floppy baby” may indicate a serious neuromuscular disorder X-LINKED MYOTUBULAR MYOPATHY (XLMTM) PATIENTS PRESENT WITH PROFOUND HYPOTONIA AND RESPIRATORY INSUFFICIENCY AT BIRTH Recognizing additional common XLMTM features1 can assist in making a diagnosis: • Facial weakness • Dolichocephaly (length and head circumference greater than 90th percentile) • Ophthalmoparesis, often associated with ptosis • Long fingers and toes • Bulbar weakness leading to insufficient sucking and swallowing • Areflexia (abnormal or absent reflexes) • Diminished muscle bulk • Decreased fetal movement and polyhydramnios during gestation • Family history of XLMTM

For more information, please visit xlmtm.com and our virtual booth at the 2021 AAN Annual Meeting Intended for U.S. healthcare professionals only 1. North K., et al. Neuromuscul Disord. 2014;24(2):97–116. doi:10.1016/j.nmd.2013.11.003.

US-XLMTM-022021-00012

EVENING ENTERTAINMENT Saturday, April 17

7:00 p.m.–8:00 p.m. ET Join us for an evening filled with the clean comedic brilliance of Jim Gaffigan! A six-time Grammy nominated comedian, actor, writer, and producer, Gaffigan is known around the world for his unique brand of humor, which largely revolves around his observations on life.

7:00 p.m.–8:00 p.m. ET

Sunday, April 18

Select from one of three popular entertainment and game night options on the virtual platform—a magic show featuring Paul Draper, The Second City Improv Comedy, or trivia.

Monday, April 19

7:00 p.m.–8:00 p.m. ET Choose your adventure! We’ll have demos for cooking, beverage tasting, and a mixologist. Have a favorite?

Visit AAN.com/networking to learn more.

7:00 p.m.–8:00 p.m. ET

Tuesday, April 20

Join us live to watch the top submissions and vote on who you think is the most talented neurologist or neuroscience professional! The top three talents will be announced at the end of the show.

AAN.com/21AM

17

The Industry Therapeutic Update is not part of the AAN official programming and there is not CME offered for attendance

EVIDENCE-BASED CANNABINOID SCIENCE TITLE

Industry Therapeutic Update from Greenwich Biosciences

SPEAKERS

Monday, April 19 7-8pm EST

Kathryn Nichol, PhD Jennifer Triemstra, MS, PhD Dewey McLin III, PhD Jessica Wolfe

VISIT OUR BOOTH

.COM

CANNABINOID

US Medical Affairs © 2021 Greenwich Biosciences, Inc.

CLINICAL CCL-18717-0321

NETWORKING/ENTERTAINMENT HUB

The Networking/Entertainment Hub is your one stop for meaningful networking opportunities throughout the Annual Meeting.

Networking Sessions

Engage in casual conversation throughout the week on different topics and themes. These video conversations are open to all.

SATURDAY

9:00 a.m.–9:45 a.m. ET How to Virtually Network at the Annual Meeting 1:00 p.m.–1:45 p.m. ET Conversation with the AAN CEO 3:00 p.m.–3:45 p.m. ET Telehealth Tips and Tricks

SUNDAY

9:00 a.m.–9:45 a.m. ET Annual Meeting Resources for Residents and Fellows 1:00 p.m.–1:45 p.m. ET Conversation with a Committee Chair 3:00 p.m.–3:45 p.m. ET Desmoralización de los servicios sanitarios. ”La segunda pandemia”

Public Chat Channels With various topics available, you can join live public text chats and move to video chats for more indepth conversations.

Private Chat Channels Do you have a chat topic not covered by the public chat channels? Create a private chat channel on the topic of your choosing and invite your colleagues to join via chat or video and discuss the things most relevant to you.

MONDAY

Direct-Messaging Reach out directly to other Annual Meeting attendees for messaging or video within the virtual conference platform.

TUESDAY

Leaderboard Earn points by attending events and visiting different areas of the virtual platform. Visit the Leaderboard to see who has earned top bragging rights for the day.

9:00 a.m.–9:45 a.m. ET Medical Students Conversation 1:00 p.m.–1:45 p.m. ET Advocacy Hot Topics and Conversation 3:00 p.m.–3:45 p.m. ET Business Administrators Conversation 9:00 a.m.–9:45 a.m. ET Cómo participar en la Resident & Fellow Section de Neurology ® 1:00 p.m.–1:45 p.m. ET The World of Advanced Practice Providers (APPs) 3:00 p.m.–3:45 p.m. ET Charting Your Leadership Journey

WEDNESDAY

9:00 a.m.–9:45 a.m. ET Current Trends Affecting Solo and Small Practice 1:00 p.m.–1:45 p.m. ET SPARK—Robin Williams and His Battle with Lewy Body Dementia 3:00 p.m.–3:45 p.m. ET How Was Your Meeting Experience?

THURSDAY

9:00 a.m.–9:45 a.m. ET How Was Your Meeting Experience?

World Map Curious about where other attendees are from? Visit the World Map to see from where your fellow attendees are participating.

Twitter Wall Check out the Twitter Wall to see what your peers are saying. Share your experience on any social media platform you are active on using #AANAM! Photo Booth Snap a selfie and share on social media. Love filters? We’ve got you covered with filters and stickers to help you personalize your picture.

AAN.com/21AM

19

COME EXPERIENCE OUR VIRTUAL BOOTH STARTING APRIL 17

Simply scan QR code or visit explorevyepti.com starting April 17

Learn more about VYEPTI and how industry experts answer the question, can we do more?

Dawn C. Buse, PhD Clinical Professor Department of Neurology, Albert Einstein College of Medicine

Andrew C. Charles, MD Professor of Neurology Director, UCLA Goldberg Migraine Program

Electra

Real VYEPTI Patient

Industry Therapeutic Update from Lundbeck is streaming live April 19, 1 PM EST The Industry Therapeutic Update is not a part of the AAN official programming and there is no CME offered for attendance. ©2021 Lundbeck. All rights reserved. VYEPTI is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100490

ALUMNI REUNIONS Looking to connect with alumni from your alma mater, along with current faculty, residents, and fellows?

Watch for information about virtual Alumni Reunions during the Annual Meeting at AAN.com/21AM. Offered during the meeting, these events will provide a great opportunity to network and catch up with your former colleagues and peers.

For Alumni Reunions or additional events, visit the Networking/Entertainment Hub on the virtual platform.

MEM: 21 Membership Dues Ad—AM Booklet Placed in AM Booklet 6 x 4.75 +0.125 bleed, 4C

Global Community

Virtual Conferences

Online Learning

Networking

Scientific Research

Count on the AAN to provide top-quality education, events, networking, and other programs and opportunities—in new virtual formats that offer greater flexibility and easy access to your worldwide neurology community. Join or renew today!

AAN.COM/MEMBERSHIP AAN.com/21AM

21

Thank You

2O21 Industry Roundtable Members*

The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.

$50,000 Members

$40,000 Members

$25,000 Members

• Medtronic

• AstraZeneca

• Grifols

• Viela Bio

• Abbott

• Ovid Therapeutics

• Adamas Pharmaceuticals, Inc.

• SK life science, a subsidiary

• Axsome Therapeutics

• UCB, Inc.

• Impel NeuroPharma

• Zogenix, Inc.

• nQ Medical, Inc.

• Alnylam Pharmaceuticals, Inc. • Amneal Specialty, a division of

Amneal Pharmaceuticals LLC • Avanir Pharmaceuticals, Inc.

$10,000 Members of SK biopharmaceuticals

• Audentes Therapeutics,

an Astellas company

• Boston Scientific

• Orphazyme • Revance Therapeutics

*Commitments as of March 5, 2021

PLENARY SESSIONS

Join us for premier sessions highlighting the latest advances in neuroscience presented by some of the most cutting-edge and well-known thought leaders in the field of neurology. Many of the sessions will have opportunities to engage with the speakers immediately following with fireside chats.

Join for Fireside Chats After Plenary Sessions Participate in live, moderated fireside chats with speakers immediately following the Frontiers in Neuroscience, Presidential, Contemporary Clinical Issues, Clinical Trials, and Controversies in Neurology Plenary Sessions. You are encouraged to submit your questions during the fireside chats for the opportunity to have speakers respond live.

Walter J. Koroshetz, MD, FAAN, Bethesda, MD

Anthony S. Fauci, MD, Bethesda, MD

Keynote Address

Hot Topics: Neuro-COVID Plenary Session Saturday, April 17 5:00 p.m.–7:00 p.m. ET For the first time, the 2021 Hot Topics Plenary Session will focus entirely on one important issue, the global COVID-19 pandemic. Join the keynote address with Walter J. Koroshetz, MD, FAAN, and Anthony S. Fauci, MD, who have been at the forefront of the public health crisis. Four outstanding speakers will then summarize their COVID-19related research findings and describe the clinical implications of their work.

Presidential Plenary Session Sunday, April 18 10:00 a.m.–1:00 p.m. ET This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2021. AAN President James C. Stevens, MD, FAAN, will kick off the session with a presentation of the President’s Award and Presidential Lecture. After that, tune in for a live address from AAN Chief Executive Officer Mary Post, MBA, CAE, followed by a few words from AAN President Elect Orly Avitzur, MD, MBA, FAAN.

Session moderators will then introduce this year's list of superb lecturers. Followed by a live fireside chat from 1:00 p.m.–2:00 p.m. ET. Contemporary Clinical Issues Plenary Session Monday, April 19 10:00 a.m.–12:30 p.m. ET This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. The first three topics will be introduced by presenters followed by a commentary from the discussant. The second half of the session will feature standalone talks on various topics.

Followed by a live fireside chat from 12:30 p.m.–1:30 p.m. ET. Clinical Trials Plenary Session Tuesday, April 20 10:00 a.m.–12:30 p.m. ET This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented. Followed by a live fireside chat from 12:30 p.m.–1:30 p.m. ET. Controversies in Neurology Plenary Session Wednesday, April 21 10:00 a.m.–12:30 p.m. ET This session features experts discussing the most current and controversial issues in neuroscience.

Tune in for a scholarly debate between two expert speakers, each advocating for one side of a single topic, followed by a rebuttal. Followed by a live fireside chat from 12:30 p.m.–1:30 p.m. ET. Neurology Year in Review Plenary Session Thursday, April 22 10:00 a.m.–12:30 p.m. ET This session looks back at the past year of research, highlighting some of the most relevant strides made in neurology subspecialties, including movement disorders, stroke, and headache. One speaker will examine how we diversify the neurology workforce.

AAN.com/21AM

23

PLENARY SESSIONS

Frontiers in Neuroscience Plenary Session Saturday, April 17 10:00 a.m.–12:00 p.m. ET This plenary session features basic and translational research related to clinical issues of importance.

Hear from five outstanding speakers as they summarize their recent research finding and dive into the clinical implications of the results. Followed by a live fireside chat from 12:00 p.m.–1:00 p.m. ET.

IN ADULT PATIENTS WITH TARDIVE DYSKINESIA (TD)

Choose INGREZZA for results you can see1

INGREZZA® (valbenazine) capsules reduced TD severity at 6 weeks, with results you can start to see as early as 2 weeks¹-³

STEP INTO A WORLD OF RESULTS YOU VISIT US AT CAN SEE INGREZZAVIRTUALBOOTH.com

Not an actual patient

Important Information INDICATION & USAGE INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

WARNINGS & PRECAUTIONS (continued)

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

Parkinsonism INGREZZA may cause parkinsonism in patients with tardive dyskinesia.

Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

WARNINGS & PRECAUTIONS Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

©2020 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-1085v2 11/2020

ADVERSE REACTIONS The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the adjacent page for Brief Summary of Prescribing Information and visit www.Neurocrine.com/INGREZZAPI for full Prescribing Information.

REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2020.

2. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebocontrolled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.

3. Data on file. Neurocrine Biosciences, Inc.

for oral use

Brief Summary: for full Prescribing Information and Patient Information, refer to package insert.

INDICATION AND USAGE INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS AND PRECAUTIONS

Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected

by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Parkinsonism INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. In the 3 placebo-controlled clinical studies in patients with tardive dyskinesia, the incidence of parkinson-like adverse events was 3% of patients treated with INGREZZA and <1% of placebo-treated patients. Postmarketing safety reports have described parkinson-like symptoms, some of which were severe and required hospitalization. In most cases, severe parkinsonism occurred within the first 2 weeks after starting or increasing the dose of INGREZZA. Associated symptoms have included falls, gait disturbances, tremor, drooling, and hypokinesia. In cases in which follow-up clinical information was available, parkinson-like symptoms were reported to resolve following discontinuation of INGREZZA therapy. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA Other adverse reactions of ≥1% incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Endocrine Disorders: blood glucose increased General Disorders: weight increased Infectious Disorders: respiratory infections Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia) Psychiatric Disorders: anxiety, insomnia During controlled trials, there was a dose-related increase in prolactin. Additionally, there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

Postmarketing Experience The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: hypersensitivity reactions (including allergic dermatitis, angioedema, pruritis, and urticaria) Skin and Subcutaneous Tissue Disorders: rash

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with INGREZZA Table 2: Clinically Significant Drug Interactions with INGREZZA Monoamine Oxidase Inhibitors (MAOIs) Clinical Implication: Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA. Prevention or Management: Avoid concomitant use of INGREZZA with MAOIs. Examples: isocarboxazid, phenelzine, selegiline Strong CYP3A4 Inhibitors Clinical Implication: Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (Cmax and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions.

Prevention or Management: Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor.

Examples: itraconazole, ketoconazole, clarithromycin Strong CYP2D6 Inhibitors Clinical Implication: Concomitant use of INGREZZA with strong CYP2D6 inhibitors increased the exposure (Cmax and AUC) to valbenazine’s active metabolite compared with the use of INGREZZA alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.

Prevention or Management: Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP2D6 inhibitor.

Examples: paroxetine, fluoxetine, quinidine Strong CYP3A4 Inducers Clinical Implication: Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy.

Prevention or Management: Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended.

Examples: rifampin, carbamazepine, phenytoin, St. John’s wort1 Digoxin Clinical Implication: Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp).

Prevention or Digoxin concentrations should be monitored when coadministering Management: INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary.

ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling: • Hypersensitivity • Somnolence • QT Prolongation • Parkinsonism Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Variable and Fixed Dose Placebo-Controlled Trial Experience The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/ schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% AfricanAmerican, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.

Adverse Reactions Leading to Discontinuation of Treatment A total of 3% of INGREZZA treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in Table 1.

Table 1:

Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and >Placebo

Adverse Reaction1 General Disorders Somnolence (somnolence, fatigue, sedation) Nervous System Disorders Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention) Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder) Headache Akathisia (akathisia, restlessness) Gastrointestinal Disorders Vomiting Nausea Musculoskeletal Disorders Arthralgia 1

INGREZZA (n=262) (%)

Placebo (n=183) (%)

10.9%

4.2%

5.4%

4.9%

4.1%

2.2%

3.4% 2.7%

2.7% 0.5%

2.6% 2.3%

0.6% 2.1%

2.3%

0.5%

1

Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

The induction potency of St. John’s wort may vary widely based on preparation.

Drugs Having No Clinically Important Interactions with INGREZZA Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 based on in vitro study results.

OVERDOSAGE

Human Experience The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.

Management of Overdosage No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

For further information on INGREZZA, call 84-INGREZZA (844-647-3992).

Distributed by: Neurocrine Biosciences, Inc. San Diego, CA 92130

INGREZZA is a registered trademark of Neurocrine Biosciences, Inc. CP-VBZ-US-0203v5 05/2020

AAN SHOWCASE The AAN Showcase is the best place at the Annual Meeting for robust information about all the products, tools, and resources the Academy has available to help you improve patient care. Engage with AAN staff who are available live via video and chat to answer your questions and share more information.

Stop by the AAN membership booth to discover what’s new and get answers to all your membership questions!

From membership applications or renewals, applying for FAAN status, engaging with Synapse Online Communities, or help navigating your member benefits, AAN membership staff will be available to assist in one-on-one chat and video calls.

Stop by for information on all of the AAN’s premier online education programs. Watch demo videos of the NeuroBytes, Annual Meeting on Demand, and NeuroReady programs; learn more about Neurology Question of the Day and NeuroSAE; and chat or video call directly with AAN staff about any of the Academy’s online learning programs.

As the philanthropic partner of the AAN, the American Brain Foundation brings researchers and donors together to invest in research across the spectrum of brain disease. Stop by our booth to learn more about research grant opportunities, how you can help fund the next generation of clinical neuroscientists, and to sign up for our annual Commitment to Cures gala.

26 2021 AAN Annual Meeting

The AAN’s Axon Registry® is a Quality Clinical Data Registry (QCDR) focused on quality improvement.

It provides real-time access to your real-world data in an online dashboard for neurologyspecific measures. Your future depends on taking control of your data to improve quality of care and reduce costs. Use the Axon Registry to set your practice up for success.

Visit with BrainPAC, the political action committee affiliated with American Academy of Neurology. Learn how our political work helps the Academy advocate for you and your patients, how you can get involved, or just come by to talk politics!

Learn what’s new with Continuum®, the AAN’s official CME journal, and Continuum® Audio. Subscribe or renew today at a 15% discount (AAN members pay only $339 per year). Offer valid through June 30 with code WMQ074AA at shop.lww.com/Continuum!

The need for equity and inclusiveness in health care has never been greater. The AAN is firmly committed to embracing Inclusion, Diversity, Equity, AntiRacism, and Social Justice (IDEAS) for our members, staff, organization, profession, and, ultimately, the patient communities we serve.

Learn more about AAN IDEAS initiatives and how we are putting our vision and mission into action.

Large shifts in the landscape of the health care industry have led to a gap between the skills that health care leaders possess and the skills their organizations need.

This gap is largely felt by physician leaders whose medical education has traditionally focused on developing excellent clinical skills, but not the fundamental leadership skills needed to advance their organizations in this changing industry. Stop by the Leadership Development Booth to learn what resources the AAN has to offer you to further your leadership development.

Visit the Neurology Career Center to find a new job, participate in a Virtual Career Fair, and view helpful resources available to support a career move. Collect a copy of the Career Compass Job Guide and learn how to claim a free t-shirt!

Watch a short video describing the print and online features of the journal and the three spin-off journals launched during the past 10 years—Neurology: Clinical Practice, Neurology: Neuroimmunology & Neuroinflammation, and Neurology: Genetics. You will also find information on the journal’s Resident & Fellow section, the Neurology Podcast, journal and podcast CME opportunities, the interactive sites Practice Current and Practice Buzz, and the four specialty mini-sites: Without Borders; Equity, Diversity, & Inclusion; Innovations in Care Delivery; and COVID-19.

Journals

Seattle is preparing to welcome you safely when we can all travel again for the 2022 Annual Meeting.

Until then, stop by for a virtual taste of the Emerald City to inspire you to start daydreaming about what you will discover next year. From unrivaled natural beauty and world-class attractions to major sports teams, a renowned arts and culture scene, and beyond, Seattle is perfect for both business and leisure. Seattle can’t wait to welcome you in 2022!

Live Inspirational Talk with Bestselling Author, Adventurer Alison Levine Alison Levine, the first American Women's Everest Expedition team captain and New York Times bestselling author, will inspire Annual Meeting attendees on Tuesday, April 20, from 1:00 p.m.–2:00 p.m. ET. Despite having been born with a life-threatening condition requiring two cardiac surgeries and suffering from Raynaud's disease, a condition that cuts the blood flow to her fingers and toes in cold temperatures leaving her at extreme risk for frostbite, she has overcome her challenges to become a history-making adventurer. Her talk ”On the Edge: The Art of High-Impact Leadership” will focus on the importance of teamwork, determination, tenacity, and the ability to adapt to changing environments as the critical keys to success in one’s life and career. She will draw on her experience as team captain to make a compelling case that the leadership principles that apply in the world of extreme adventure also apply to today’s rigorously competitive work environments.

Be sure to stay after the 45-minute talk for a question and answer session.

Sponsored by AAN Family of Publications, Neurology®, Neurology® Clinical Practice, Continuum®, Neurology Today®, and Brain & Life® with Wolters Kluwer Health, AAN Publishing Partner.

AAN.com/21AM

27

Awards Theater

The Awards Theater will celebrate the achievements of neurology and neuroscience professionals. Watch a welcome video from AAN President James C. Stevens, MD, FAAN, presentations from scientific award recipients about their research, and recognize your peers who are being honored in 2021 throughout the theater. Visit AAN.com/21AM to view a complete list of award recipients.

EDUCATION AWARDS A.B. Baker Award for Lifetime Achievement in Neurologic Education John Engstrom, MD, FAAN University of California, San Francisco

AWARDS THEATER

”On behalf of the Engstrom and UCSF Neurology families, I offer my deepest thanks to the A.B. Baker Review Work Group and AAN for my selection as recipient of the 2021 A.B. Baker Lifetime Achievement in Neurologic Education award. I have been honored to contribute to the establishment of neurology medical education as a viable faculty career choice in the US.”

A.B. Baker Teacher Recognition Award Aman Deep, MD

Barney J. Stern, MD

Andrew R. Romeo, MD

Barry M. Czeisler, MD

Anna M. CervantesArslanian, MD

Catherine E. Arnold, MD

Aravindhan Veerapandiyan, MD

Chilvana Patel, MD

Arpan Patel, MD

Christopher G. Tarolli, MD, MHPE

Professor of Neurology Appalachian Regional Healthcare

University of Michigan

Johns Hopkins University

New York University Grossman School of Medicine

Mayo Clinic

Boston University School of Medicine, Boston Medical Center

University of Texas Medical Branch

Arkansas Children's Hospital / University of Arkansas for Medical Sciences

Northwell Health (North Shore University Hospital & Long Island Jewish Medical Center)

28 2021 AAN Annual Meeting

University of Rochester

Cynthia M. Correll, MD

Geisinger Commonwealth School of Medicine

James Warne Schmidley, MD Virginia Tech Carilion School of Medicine

Danish Ejaz Bhatti, MD, FAAN

Jason S. Hawley, MD

David K. Chan, MD, Med

Jayne Ward, DO, FAAN, FACN

University of Nebraska Medical Center

University of Toronto

Walter Reed National Military Medical Center

Michigan State University

Dinesh V. Jillella, MD

Jeffrey M. Gelfand, MD, MAS, FAAN University of California, San Francisco

AWARDS THEATER

Emory University School of Medicine

Mayo Clinic

Jennifer A. McCombe, MD, MPH, FRCPC

Eric J Seachrist, MD

Jeremy J. Laukka, PhD

West Virginia University

University of Toledo College of Medicine and Life Sciences

Fariha Jamal, MD Baylor College of Medicine/

Joseph D. Burns, MD

Jaime Toro, MD, FAAN, FACP

Kevin M. Kelly, MD, PhD

James M. Noble, MD, MS, CPH, FAAN

Matthew Burford, MD

Elliot Dimberg, MD

Michael E. DeBakey VA Medical Center

University of Alberta

Lahey Hospital and Medical Center; Tufts University School of Medicine

Allegheny General Hospital

Fundacion Santa Fe de Bogota

Cedars-Sinai Medical Center

Columbia University

AAN.com/21AM

29

A.B. Baker Teacher Recognition Award Geetanjali Rathore, MD University of Nebraska Medical Center

Children's Hospital of Philadelphia/ University of Pennsylvania

Mostafa Meshref

Susan W. Law, DO, MPH

Al-Azhar University

SUNY Downstate Medical Center

Naoum P. Issa, MD, PhD

Timothy Fullam, MD

Nicole Chiota-McCollum, MD, MEd

Tuba Rashid Khan, MBBS, MPH, EdM

University of Chicago

AWARDS THEATER

Sudha Kilaru Kessler, MD, MSCE

University of Virginia

United States Air Force

University of Texas Southwestern Medical Center

Nils Henninger, MD, PhD

Victor W. Sung, MD

University of Massachusetts Medical School

University of Alabama at Birmingham

Preet M Varade, MD

Waqar Waheed, MD

Pazhani Ranganathan, MD, DM, MRCP, FRCP, FEBN, FEAN, LLB

William J. Powers, MD

Saad Abdul Sami Mir, MD

Zabeen Kaizar Mahuwala, MD

Lehigh Valley Health Network

Pazhani Neuro Centre/The Tamilnadu DR.M.G.R Medical University

Weill Cornell Medical College

Sean J. Evans, MD UC San Diego

30 2021 AAN Annual Meeting

University of Vermont Medical Center

University of North Carolina School of Medicine

University of Kentucky

Association of Indian Neurologists in America Lifetime Achievement Award Seemant Chaturvedi, MD University of Maryland

“I am very grateful to the selection committee for the honor of the Lifetime Achievement Award. I have participated in AINA activities for more than 15 years and witnessing the growth of the organization has been very rewarding. I would like to acknowledge the support of my previous mentors and many esteemed professional colleagues, especially in the cerebrovascular community. Finally, I would like to thank my wife, children, and other close family members for their unwavering support and encouragement.”

Manmohan Nayyar, MD, FAAN, MBA, MHA Choice Medical Group

Clerkship Coordinator Recognition Award Sheryll Marshall University of Michigan

”I would like to thank Dr. Douglas Gelb for his nomination. I have enjoyed working with him and the medical student program for over 23 years. I am truly honored to receive this award. Thank you for recognizing my hard work and dedication to the student program!”

M. Bernadette Clark Johns Hopkins University

”Thank you very much for selecting me to receive the Clerkship Coordinator Award. This is clearly one of the most significant events of my professional career.”

Clerkship Director Innovation Award Doris G. Leung, MD, PhD Johns Hopkins University School of Medicine

”This year has been one of innovation by necessity for all clerkship directors, and it is truly an honor to be selected by the American Academy of Neurology for this award. Thanks also to our neurology clerkship team, administrators, and students for their dedication and support.”

AAN.com/21AM

31

AWARDS THEATER

”I am honored to receive the 2021 Association of Indian Neurologists in American Lifetime Achievement Award. I would like to thank AINA, American Brain Foundation, the nominating committee, previous AINA Lifetime Achievement Award recipients, and my nominators. During my career, I had the opportunity to collaborate with many fine and smart people and I would like to thank them all for productive interactions and prolific exchange of ideas. I cannot name them all here but each one of you have influenced me in a positive way. Thank you.”

AWARDS

Clerkship Director Innovation Award Madhu Soni, MD, FAAN Rush University Medical Center

”I'd like to dedicate this invaluable honor to my parents, my very first teachers, and share the recognition with students and colleagues from whom I have learned. My sincere gratitude to the AAN and to all who have contributed to the privilege and opportunity to educate.”

Consortium of Neurology Residents and Fellows Essay Contest Jonathan Williams, MD

AWARDS THEATER

Washington University

”I thank the AAN for organizing this honor. I dedicate this writing to my predecessors, who created this opportunity to share my passion. Special acknowledgement to my wife, Ty, and son, Levi, who are my guiding light. I thank my parents for their perpetual love and support. I thank all my mentors at every stage, but a special thanks to Drs. Mwiza Ushe, Ed Hogan, and Jean Cibula. I acknowledge the WashU Neurology residency and department under Dr. Joy Snider and Dr. David Holtzman, respectively. Lastly, I acknowledge Howard University for enriching my medical education with emphasis on social justice.”

Frank A. Rubino Award for Excellence in Clinical Neurology Teaching Michael Schneck, MD Loyola University Chicago, Stritch School of Medicine

”I am immensely grateful to the AAN for honoring me with the Frank Rubino Award. 'I have learned much from my teachers, more from my colleagues, and the most from my students' (Rabbi Chanina, Babylonian Talmud). This award honors them as much as it does me. I also thank my patients, who are my raison d'etre. I thank my wife, Mary, and family for their ongoing love and support. Most of all, I thank my mother, and especially my late father. Larry Schneck was a pediatric neurologist and neurochemist whose love of family, commitment to patients, and dedication to neurology remains a continuing inspiration.”

32 2021 AAN Annual Meeting

Residency-Fellowship Program Coordinator Recognition Award Jean Peng, MPH Mount Sanai Beth Israel

Samantha Kunvatanagarn University of Pittsburgh's Medical Center Neurology

Tracey White, BS Emory Brain and Health Center

Malinda Scott, CMA, C-TAGME University of Arkansas for Medical Sciences

Residency-Fellowship Program Director Recognition Award Chad Carlson, MD Medical College of Wisconsin

Torrey Boland-Birch, MD Department of Neurological Sciences Rush University Medical Center

Jeremy Moeller, MD, MSc, FRCPC Yale University

Rebecca Fasano, MD Emory University

YOU DON’T WANT TO MISS THIS.

Sanjay Gupta, MD Public Leadership in Neurology Award

April 21, 2021 • 8-9 p.m. ET Don’t miss out on Commitment to Cures, a virtual event dedicated to celebrating and supporting advances in brain disease research. The evening will feature celebrity guests, a musical performance by Grammynominated singer and songwriter Alex Newell, a craft cocktail demo, inspiring stories from those impacted by brain disease, and more!

And don’t forget to purchase your raffle ticket for a chance to win a getaway in Tuscany!

Cindy McCain Commitment to Cures Award

Jim Cramer Master of Ceremonies

Get your ticket when you register for the AAN Annual Meeting or visit AmericanBrainFoundation.org/C2C2021 Alex Newell Musical Performer

AAN.com/21AM

33

PATIENT SERVICE AWARDS Ambassador Award NFL Players Association Health & Safety Committee The NFL Players Association's Health & Safety Committee is honored for its work protecting players from and raising awareness of sports concussion. The committee was formed in 2009 to help develop health and safety policies in the workplace for past, present, and future player members.

Commitment to Cures Award Cindy McCain Cindy McCain is honored for her awareness-building and philanthropic work she has initiated for glioblastoma. She joined the American Brain Foundation board of directors in January 2020 to help raise disease awareness in the public conscience. Her fundraising work has helped advance neuroscience research and patient care.

AWARDS THEATER

Mridha Spirit of Neurology Humanitarian Award Farrah Mateen, MD, PhD Massachusetts General Hospital / Harvard Medical School

“In a year when so many people have made sacrifices during the global pandemic, the myriad roles of a neurologist as advocate, researcher, clinician, teacher, and team player have never been so clear. I thank the American Brain Foundation, who funded my fellowship a decade ago and allowed me to take a non-traditional career path.

I share this award with my colleagues all over the world who demonstrate that advancing the care of people with neurologic disorders is a collective passion.”

Deanna Saylor, MD, MHS Johns Hopkins University School of Medicine / University of Zambia School of Medicine / University Teaching Hospital

“Thank you to the American Brain Foundation, the AAN, and the Mridha family for the honor of being selected as this year’s recipient of the Spirit of Neurology Award. At a time when the COVID-19 pandemic has reminded us just how interconnected our health is, it is wonderful to see an award that honors efforts to improve care for underserved populations. Working to improve neurologic training and care in Zambia has been the most rewarding part of my career, especially as we strive to bring equity to neurologic care across the world.”

Sanjay P. Singh, MD, FAAN, FANA Creighton University School of Medicine

“I am humbled and honored to receive this award. I would like to thank the AAN and the American Brain Foundation for this award.

I dedicate this award to my parents who taught me the value of service. I feel such gratitude towards the patients, from around the world, who have allowed me the privilege to serve them. I have always been inspired by Gandhi’s words, ‘The best way to find yourself is to lose yourself in the service of others.’ This award exemplifies that spirit. And finally, I would like to thank the Mridha Endowment Fund.”

34 2021 AAN Annual Meeting

QI Innovation Award Mahjabin Islam, MBBS, MRCP; Ahmed Mubarak-Mohamed, MRCPE; Tom Jenkins, MBChB, MRCP, PhD; Christopher McDermott, MBChB, FRCP, PhD Royal Hallamshire Hospital

”I am incredibly honored to receive the 2021 QI Innovation award.

This award will be an encouragement for me to continue my research in MND. Thanks to the American Academy of Neurology for recognizing our quality improvement work to provide compassionate care to motor neuron disease patients. In Sheffield MND Centre, we tailor our service based on the national guideline, evidence base, and patient feedback and aim to continuously improve the quality of care. We are immensely grateful to our patients, hospital, and community team looking after MND patients and the fantastic support that we receive from Sheffield Teaching Hospitals.”

Dara VF Albert, DO, MEd; William Parker, CPHQ; Nancy Auer, APN; James Herbst, PharmD; Daniel A. Freedman, DO; Shawn Aylward, MD; Rae Gumayan, MD; Daniel Cohen, MD; Michael Perry, MD; Julie Chrisman, RN; Anup D. Patel, MD ”I would like to thank the American Academy of Neurology for recognizing our important work on improving utilization of seizure action plans for children with seizures. I would like to thank and acknowledge our amazing multidisciplinary team, especially our Quality Improvement Specialist, Will Parker. We hope our work can spur interest in other programs adopting and implementing seizure action plans for pediatric epilepsy patients in their care.”

Ted Burns Humanism in Neurology Award John Quinlan, MD University of Cincinnati Medical Center

Dr. Quinlan is one of those rare individuals who has accomplished a tremendous amount in all domains of teaching, patient care, and research. Over the past 33 years, he has been an outstanding neurologist, exceptional scholar, and an educational leader within the neuromuscular field, as well as a leader in general within the University of Cincinnati College of Medicine and Medical Center.

Public Leadership in Neurology Award Sanjay Gupta, MD Dr. Gupta is honored with the Public Leadership in Neurology Award for his role in raising public awareness of brain health. As a neurosurgeon and neuroscientist who has become America’s doctor, and through his new book, Keep Sharp, Dr. Gupta has made a massive contribution to the public’s awareness of brain health for overall health.

Scientific Breakthrough Award Peter Goadsby, MD, PhD Professor Goadsby’s seminal research led to the development of biologics and drugs that block the CGRP pathway, which has changed the lives of so many people with migraine.

AAN.com/21AM

35

AWARDS THEATER

Nationwide Children's Hospital

SCHOLARSHIPS International Scholarship Award

Mar Guasp, MD Barcelona, Spain

Gianmarco Abbadessa, MD Naples, Italy

Ifeyinwa Ani-Osheku, MBBS

Katrina Hannah Ignacio, MD Manilla, Philippines

Asokoro, Nigeria

Moises Misael Rubio Hernandez, MD Luca Baldelli, MD

Zapopan, Mexico

Bologna, Italy

Ummugulsum Koc, MD

AWARDS THEATER

Bochum, Germany

Hanna Demissie Belay, MD Addis Ababa, Ethiopia

Anand Kumar, DM Varanasi, India

Rok Berlot, MD, PhD Ljubjana, Slovenia

Durjoy Lahiri, MD, DM Kolkata, India

Mashina Chomba, MBChB Lusaka, Zambia

Shanglin Li, MD Beijing, China

Marcelo de Brito, MD São Paulo, Brazil

Jingyi Liu, MD Beijing, China

Daniela Laura Giardino, MD Buenos Aires, Argentina

Amina Mohamed, MD Eldoret, Kenya

36 2021 AAN Annual Meeting

Gabriel Pinilla Monsalve

Mei-Jun Shu, MD

Amina Nasri, MD

Duncan Street, MBBS, MRCP

Cali, Colombia

Tunis, Tunisia

Beijing, China

Birmingham, United Kingdom

Samir Patel, MD, DNB Ahmedabad, India

Ya Su, MD

Shanghai, China

Hebatallah Rashed, MD, PhD

Naohiro Uchio, MD, PhD

Mario Ricciardi, MD

Maria Agustina Ruiz Yanzi, MD

Tokyo, Japan

Buenos Aires, Argentina

AWARDS THEATER

Cairo, Egypt

Buenos Aires, Argentina

Lokesh Saini, DM

Garik Yeganyan, MD

Laura Sander, MD

Nisa Vorasoot, MD

Basel, Switzerland

Khon Kaen, Thailand

Raul Anwar Garcia Santos, MD

Gulshan Yunisova, MD

Yi Shen, MD

Ramdinal Aviesena Zairinal, MD

Chandigarh, India

Vanadzor, Armenia

Istanbul, Turkey

Mexico City, Mexico

Zhejiang, China

Depok, Indonesia

AAN.com/21AM

37

Neuroscience Research Training Scholarship Emily Ferenczi, MD, PhD Massachusetts General Hospital, Brigham, Harvard

“I am deeply honored to receive a 2021 AAN Neuroscience Research Training Scholarship. This award provides an invaluable opportunity to pursue my research investigating the neural circuit basis of movement disorders, with the goal of bringing new understanding and hope for our patients. Thank you to the AAN for supporting me and to my wonderful mentor, Dr. Bernardo Sabatini, for his enthusiasm and expert guidance.”

Frederike Cosima Oertel, MD University of California, San Francisco

AWARDS THEATER

“Thank you for selecting me as a recipient of AAN’s 2021 Neuroscience Research Training Scholarship. It is an honor to have my work recognized at this early stage of my career; the award will be a great booster to continue doing my best work. I would like to thank all my mentors, who guided me through my career so far, as well as my family, friends, and colleagues for their unconditional support.”

Practice Research Training Scholarship Altaf Saadi, MD Massachusetts General Hospital, Brigham, Harvard

“I am so grateful to receive this award, which will be instrumental in understanding and addressing health disparities among patients with neurologic illness. I am especially honored to follow in the footsteps of impressive clinician-researchers whose impactful careers were kickstarted by support from the AAN early in their careers. Lastly, I see this award as a testament to AAN’s recognition of health disparities as a priority research area in neurology.”

Resident Research Scholarship Aditi Varma-Doyle, MD LSU Health New Orleans

“Thank you to the AAN for this opportunity, and thank you to mentoring faculty Drs. England, Lelorier, and Pittman at LSUHSC for their support and collaboration in this project. We aim to understand the autonomic and other physiological changes caused by the SARS-CoV-2 virus via its effect on small fiber nerves, and potential consequences of such an effect.”

Elizabeth Harrison, MD UPMC Children's Hospital of Pittsburgh

“It is an honor to be a recipient of this year's AAN Resident Research Scholarship. I am so grateful to the AAN for supporting my project and for encouraging me to develop my research career while still in training. I am also tremendously thankful for my mentoring team, as well as for the other residents and fellows in my program; their support throughout this process has been invaluable.”

38 2021 AAN Annual Meeting

Linda Nyugen, MD, PhD University of California, San Diego/Rady Children's Hospital

“Thank you to the AAN for this great honor of receiving the 2021 Resident Research Scholarship. I would like to thank all my mentors who guided me through my residency training so far with special thanks to Dr. Jennifer Graves and neurology faculty at Rady Children’s Hospital and University of California San Diego.”

SCIENTIFIC AWARDS AAN Neuro-infectious Disease Award Deanna Saylor, MD, MHS Johns Hopkins University School of Medicine

”I would like to thank the AAN for this incredible honor. The AAN has been a valued and important resource in my career by providing opportunities for networking, building collaborations, and funding. The Neuro-Infectious Disease Section is an immense resource with senior clinicians and researchers whose neuro-infectious disease expertise has inspired and helped me to build my own career.”

Mehdi Bouslama, MD Emory University School of Medicine

”It is a true honor to be the recipient of this year's Alliance Founders Award, and I thank the AAN for this recognition. I would like to thank all my mentors who helped me throughout my academic journey and especially Professor Raul Nogueira. Thank you also to my family for their boundless love and support.”

Bruce S. Schoenberg International Award in Neuroepidemiology Guillermo Delgado-Garcia, MD, MSc University of Calgary

”Thank you! I am deeply honored to receive the Bruce S. Schoenberg Award this year. This distinction is, of course, a decisive spur for my budding career in neuroepidemiology. I would like to thank my mentors, Drs. Teresa Corona, Mayela Rodríguez-Violante, and Germán Fajardo-Dolci, for their continued encouragement along the way. Last, but not least, I am certain that this would not have been possible without the absolute support of Carolina, my wife.”

Career Development Award Jason Chua, MD, PhD University of Michigan

”I am incredibly grateful to the AAN for funding my proposal to study how autophagy—a specialized pathway of protein degradation—can improve neuron survival in Parkinson’s Disease (PD). I also thank the AAN’s grant reviewers, funding sources, and benefactors, whose generosity has advanced the fight against PD and brings our research closer to discovering safe and effective treatments for PD patients.”

AAN.com/21AM

39

AWARDS THEATER

Alliance Awards: Founders

Career Development Award Julie Miller, MD, PhD Massachusetts General Hospital

”I am grateful to be recognized by the AAN with this Career Development Award. As a junior investigator, the support offered by this award will be instrumental in advancing my research program in gliomas. I am truly thankful for the AAN for this award, and the guidance, support, and inspiration of my mentors, colleagues, and patients.”

Clinical Research Training Scholarship Daniel Rubin, MD, PhD Massachusetts General Hospital

”I wish to thank the AAN for awarding me one of the 2021 Clinical Research Training Scholarships. I am incredibly grateful to the Academy for this prestigious award and I am proud to be a part of an organization that does so much to advance the basic and clinical science aimed at bringing meaningful change to the lives of patients.”

AWARDS THEATER

Samuel Snider, MD Brigham and Women's Hospital, Harvard Medical School

”I would like to thank the AAN for seeing the value in this project.

I would like to thank my mentors, Dr. Edlow, Dr. Fox, and Dr. Jain for their dedication and guidance. I would also like to thank Dr. Batchelor, chair of the department of neurology at the Brigham and Women’s Hospital, for providing support over the last year. I look forward to working hard toward making an impact on the lives of patients with traumatic brain injury.”

Yan Wang, MD Washington University in St. Louis

”I would like to thank the AAN for awarding me a Clinical Research Training Scholarship. Through the AAN’s generosity, I can dive into innovative research on cerebral small vessel disease.

Importantly, I would also like to thank my mentors, letter writers, and the neurology department at Washington University for supporting my career development.”

Clinical Research Training Scholarship in ALS Jonathan Brent, MD, PhD Feinberg School of Medicine, Northwestern University

”I am absolutely thrilled to have been awarded the Clinical Research Training Scholarship in ALS. It means so much to have the support of such prestigious organizations as the AAN, The ALS Association, and American Brain Foundation. I am very thankful for this outstanding opportunity to impact the lives of my patients and build my research skill through completion of this exciting project. I look forward to working and networking with you all.”

40 2021 AAN Annual Meeting

Clinical Research Training Scholarship in ALS and Related Disorders Ikjae Lee, MD Columbia University Medical Center

”It is my highest honor to receive the 2021 Clinical Research Training Scholarship Award in ALS and Related Disorders. I will investigate the alteration in lipids to understand the changes in metabolism stemming from motor neuron degeneration. I truly appreciate the scholarship from the AAN supported by the CReATe Consortium and the American Brain Foundation that would enable me to focus on this research project and grow my career as a clinician investigator.”

Clinical Research Training Scholarship in Neuromuscular Disease Renatta Knox, MD, PhD Nationwide Children's

AWARDS THEATER

”It is an honor to be a recipient of the 2021 Clinical Research Training Scholarship in Neuromuscular Disease. Research has been a passion of mine since I was an undergraduate and this award will allow me to pursue important translational research on muscular dystrophy. I would like to thank the AAN, Muscle Study Group, and American Brain Foundation for this opportunity and my exceptional research mentor Dr. Scott Harper for creating a rich and supportive environment where we can tackle important translational problems.”

Clinical Research Training Scholarship in Parkinson's Disease Helen Hwang, MD, PhD Washington University in St. Louis

”I am extremely honored and grateful to receive this award from the AAN. This opportunity will provide me with support and encouragement for the early stages of my career. I sincerely thank my family and my research and clinical mentors for guidance and inspiration—Dr. Paul Kotzbauer, Dr. Andrea Soranno, Dr. Joel Perlmutter, Dr. Albert Gus Davis, and Dr. Mwiza Ushe. Many thanks also to the movement disorders department at Washington University in St. Louis for their ongoing support.”

Dreifuss-Penry Epilepsy Award Anli Liu, MD NYU Langone Health

”I am honored and humbled to receive the 2021 Dreifuss-Penry Award. I thank Bruce Miller (USCF), who seeded an early interest in memory and neurology. Orrin Devinsky and Gyorgy Buzsaki (NYU) have inspired me to ask big questions and have generously opened many doors for me. Thank you to Simon Henin, Helen Borges, and my collaborators, colleagues, and patients. Finally, thank you to my family and friends who remind me to laugh.”

AAN.com/21AM

41

H. Richard Tyler Award Michael Young, MD, MPhil MGH-BWH Harvard Medical School

”I am deeply grateful and honored to receive the H. Richard Tyler Award from the AAN. I thank my incredibly dedicated mentors and extraordinary colleagues at MGH-BWH Harvard Medical School for support my goals.”

Harold Wolff-John Graham Award: An Award for Headache/Facial Pain Research Rebecca Erwin Wells, MD Wake Forest Baptist Medical Center

AWARDS THEATER

”I am so honored to receive this prestigious award. I am so thankful to the AAN for this recognition. This award reflects my mentors’ dedication to my career, the extraordinary team effort of each research team member, and my family's support. Weekly during my headache fellowship at the John R. Graham Headache Center, we read a chapter from Wolff’s textbook of Headache Medicine. I am hopeful this headache research honors their legacy.”

Irwin Schatz Award for Autonomic Disorders Christopher Gibbons, MD, FAAN Harvard Medical School

”I am deeply honored to receive the Irwin Schatz Award for Autonomic Disorders from the American Academy of Neurology.

Irv Schatz was a founding member of the American Autonomic Society, and integral to the development of the field of autonomic disorders. Irv was a wonderful teacher, a caring physician, and a distinguished investigator.

I’m extremely grateful to my colleagues, mentors, and the AAN for this award in his name.”

John Dystel Prize for Multiple Sclerosis Research Vijay Kuchroo, MD Brigham and Women's Hospital, Harvard Medical School

”I am extremely honored to be receiving Dystel Prize for 2021 and I sincerely thank the committee for choosing me for the award this year. Seeing MS patients for the first time in the MS clinic with Howard Weiner provided me both inspiration and strength to study the disease and develop animal models that could be used to develop a better understanding and treatments for the devastating disease.”

42 2021 AAN Annual Meeting

Jon Stolk Award in Movement Disorders for Young Investigators Ian Bledsoe, MD University of California

”I am deeply honored to be the recipient of the 2021 Jon Stolk Award and sincerely thank the AAN for this recognition. I am grateful for outstanding mentorship from Dr. Jennifer Goldman. I must also thank the faculty at Rush University who supported me throughout fellowship with inspired guidance. Finally, I thank my wonderful team and colleagues at UCSF for their dedication to our patients and to moving our field ever forward.”

Lawrence C. McHenry: An Award for the History of Neurology Bart Lutters, MD, MSc University Medical Center Utrecht

McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory Loss Matthew Burns, MD, PhD University of Florida College of Medicine - Neurology

”I am thrilled to receive this award and profoundly grateful to the AAN, the McKnight Brain Research Foundation, and American Brain Foundation for the recognition, support, and protected time it provides. I would also like to thank the unwavering support of my mentors Drs. Barry Setlow, Jen Bizon, and Michael Okun, and the many inspiring patients of the Norman Fixel Institute for Neurological Diseases at the University of Florida.”

Wai-Ying Yau, MD Massachusetts General Hospital, Brigham, Harvard

”I would like to thank the AAN and the McKnight Brain Research Foundation for the scholarship and for their commitment to fostering the development of early-career physician-scientists like myself. I am deeply grateful to my mentors Drs. Reisa Sperling and Jasmeer Chhatwal for their unwavering support and guidance, and to my medical school mentor Dr. William Klunk for his ongoing support.”

AAN.com/21AM

43

AWARDS THEATER

”I wish to thank the American Academy of Neurology for supporting my research in the history of neurology. Reflecting on neurology's past installs medical students, physicians, and researchers with a flexible attitude towards the continuous developments in our field. It is an honor to contribute to this cause through my work.”

Medical Student Essay Award: Extended Neuroscience John Michael Sanchez, PhD University of Utah

”I am grateful to the American Academy of Neurology for the Extended Neuroscience Award. Tremendous thanks to my research advisor, Dr. Robert S. Fujinami, and my clinical mentor, Dr. Stacey L. Clardy, for helping shape my physician scientist career. Thanks also to Bia DePaula-Silva, Daniel Doty, Tyler Hanak, Amanda Truong, and Jane Libbey, without whom this work would not have been possible.”

Medical Student Essay Award: G. Milton Shy Aparna Nutakki

AWARDS THEATER

University of Chicago

”I am honored to receive this award from the AAN. I am further grateful for the AAN Medical Student Research Scholarship that made this research possible. I would like to thank Dr. Deanna Saylor and the Neurology team at University Teaching Hospital in Lusaka, Zambia, for welcoming me into their community, and for their continued support and teamwork throughout our research.”

Medical Student Essay Awards: Roland P. Mackay Duong Chu Queen's University

”I am honoured to receive this award and would like to thank the AAN for their support of my passion for History of Neurology!

As an aspiring future neurologist, it is inspiring to recognize the contributions made to the field by those before me and apply those lessons learned. I hope to continue exploring this rich aspect of neurology in my future career.”

Medical Student Essay Awards: Saul R. Korey Abena Kwegyir-Aggrey Penn State College of Medicine

”I’m honored to receive the Saul R. Korey Award. I’d like to thank Dr. Lowden, Dr. Sun, and Dr. Hennessy for their guidance, and my colleague April Henry for her significant contributions to the project. I’m grateful to Dr. Baskerville for fueling my interest in neuroscience and to my mentor, Dr. Fisher, for her endless support and encouragement. It’s a privilege to represent Penn State College of Medicine.”

April Henry Penn State College of Medicine

"I would like to thank the AAN for granting Abena Kwegyir-Aggrey and me the opportunity to share our research on Combating Neurophobia: Neurology Exposure in Preclinical Years and Residency Match Trends. This opportunity has been humbling and is greatly appreciated as it has provided an avenue for us to contribute the field of neurology. I would also like to thank the selection committee for selecting our essay for the Saul R. Korey Medical Student Essay Award."

44 2021 AAN Annual Meeting

Michael S. Pessin Stroke Leadership Prize Guido Falcone, MD Yale School of Medicine

”Thank you to the AAN and the selection committee—it is an immense honor to receive this year's Michael S. Pessin Stroke Leadership Prize. This is an exciting time for the fields of population genetics and genomic medicine. I am therefore grateful that this award recognizes an investigator and research program focused on these topics.

I am also extremely grateful with my mentors, colleagues, and research partners.”

Mitchell B. Max Neuropathic Pain Award Stephen G. Waxman, MD, PhD, FAAN Yale School of Medicine

Movement Disorders Research Award Roger Albin, MD University of Michigan

”It’s very gratifying to receive the 2021 AAN Movement Disorders Research Award. It’s a privilege to be able to contribute to such a vital area of neurologic research and practice. This award is largely attributable to the outstanding training I received from my mentors, Anne Young and the late Jack Penney, and the opportunity to collaborate with many talented investigators at the University of Michigan.”

Neuro-oncology Investigator Award Pratiti Bandopadhayay, MBBS, PhD Harvard Medical School

”Thank you to the American Academy of Neurology for this tremendous honor for my lab and I. We all have much work to do to find more effective and less toxic treatments for children who are diagnosed with brain tumors—the number one solid tumor of childhood, and the leading cause of cancer-related death. Our patients, their families and our colleagues across the world provide a constant beacon of motivation for us to work. Thank you to you all!”

AAN.com/21AM

45

AWARDS THEATER

”I would like to thank the AAN for this enormous honor. More broadly, I thank the AAN for moving the field of neurology ahead and for launching countless careers. I’m grateful to my mentors and my collaborators. Even more, I am grateful to my students who have taught me so much. Finally, I owe a debt to the many patients who, in sharing their DNA and their stories, have helped to unravel the mysteries of neurological disease.”

Neuro-oncology Scientific Award Michelle Monje, MD, PhD Stanford University

”I would like to thank the AAN for the honor of the Neurooncology Scientific Award supported by the friends of Dr. WK Alfred Yung. I am grateful to my scientific and clinical mentors in neuroscience, cancer biology, neurology and neuro-oncology, for the opportunity to both mentor and learn from each of the members of my lab, to my collaborators in diverse fields from whom I have learned so much and to my patients, who inspire and motivate all the work that we do.”

Neuroscience Research Prize Noah Getz

AWARDS THEATER

The Bronx High School of Science

”I am so honored to be selected as a recipient of the 2021 Neuroscience Research Prize. Most of all, I am excited to attend this year's Annual Meeting, where I will get to hear from so many groundbreaking scientists in the field of neurology. My favorite aspect of science has always been its innately communal nature, so I cannot wait to immerse myself in every exchange of ideas the conference has to offer.”

Danny Li Jericho Senior High School

”I would like to thank Dr. McCalla for her sheer dedication and unending belief in me. I would also like to thank my mentor, Dr. Wei Zhu, for his endless guidance throughout the development of my research project. Lastly, I would like to thank my friends and family for supporting me throughout the demanding yet rewarding research endeavors that I have learned so much from.”

Neuroscience Research Prize Viraj Mehta BASIS Scottsdale

”I am honored and excited to receive the 2021 AAN Neuroscience Research Prize. It is truly humbling to be selected, and I am incredibly grateful to the American Academy of Neurology for this recognition of my work intersecting artificial intelligence and neuroscience.

Receiving the prize has also further inspired me in my endeavors to research neurologic diseases like glioblastoma.”

Neuroscience Research Prize in Child Neurology Meagen Ryan Ossining High School

”I wish to express my sincerest gratitude to the American Academy of Neurology for selecting me to be a recipient of the 2021 Neuroscience Research Prize. It is an honor to have my research recognized by such a prestigious organization. I am ecstatic to attend, and even more so to present at the 2021 Child Neurology Society Annual Meeting. Thank you to the American Academy of Neurology, my mentors, teachers, and peers who have made this possible.”

46 2021 AAN Annual Meeting

Norman Geschwind Prize in Behavioral Neurology Hugo Botha, MD Mayo School of Graduate Medical Education

”I am honored to receive the Norman Geschwind Prize in Behavioral Neurology. Dr. Geschwind’s focus on detailed phenotyping continues to motivate me as a clinician, while his revolutionary work on aphasia inspires me as a researcher. I am privileged to have a mentorship team as dedicated to behavioral neurology as he was, some of whom trained under him or his early graduates. I hope to uphold this tradition of excellence throughout my career.”

Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases Kenneth S. Kosik, MD University of California Neuroscience Research Institute, Santa

AWARDS THEATER

”No greater honor can be bestowed on one’s research than recognition by colleagues. So, my gratitude goes to the Potamkin family for establishing an award through which our field can mark steady progress toward lighting a path, the only path—research— that will lead to a cure. I have investigated tau since I was a postdoc and am so pleased to see the role of tau become increasingly clear due to the dedication and persistence of many scientists.”

Giovanna Mallucci, MD, PhD University of Cambridge

”I am truly delighted and deeply honored to receive the 2021 Potamkin Prize. It is a tremendous endorsement of my lab's mission to discover ways to treat these currently incurable diseases—that touch so many of our lives—by targeting common dysregulated pathways. The prize comes at a very exciting time for the translation of our research and strengthens my resolve to drive our discoveries towards new therapies.”

Richard Olney Clinician Scientist Development Award in ALS Paul Sampognaro, MD University of California, San Francisco

”I feel truly honored and grateful to have received this award.

I am immensely thankful to Dr. Aimee Kao and Dr. Catherine Lomen-Hoerth for their mentorship and guidance as well as to the AAN, The ALS Association, and the American Brain Foundation for supporting my research. This grant will permit me the necessary time and resources to develop my career as an early investigator and to continue pursuing my translational research efforts, aimed at finding novel therapies for patients with ALS.”

AAN.com/21AM

47

Sheila Essey Award: An Award for ALS Research Jan Veldink, MD, PhD UMC Utrecht

”Receiving the 2021 Sheila Essey Award is a tremendous honor for me. I would like to especially thank the Essey family and the ALS Association. Looking at the list of past awardees, I can hardly believe to be receiving this year's edition of the award. This truly is a recognition for all the efforts I and others make to gain insight into the complete genetic basis of ALS, knowing that genetic findings nowadays can translate to new therapies.”

Sleep Science Award Charlene Gamaldo, MD, FAAN

AWARDS THEATER

Johns Hopkins University

”Thanks, first and foremost, the AAN Sleep Science Award group then my nominator Dr. Rachel Salas. I am truly honored. Thank you AAN, the sleep research community, my collaborative team of sleep researchers and my subjects/patients; without whom I couldn’t have realized my dream to further our knowledge of the intricate relationship between sleep biology and neurological function. Finally, my family—without them none of this would be possible.”

Susan S. Spencer, MD, Clinical Research Training Scholarship in Epilepsy Samuel Terman, MD University of Michigan

”I am extremely grateful for the honor of being selected to receive the Susan S. Spencer award. This support will undoubtedly accelerate my career by providing the protected time and educational resources necessary to execute my research goals, and advance me towards becoming an independent physician-scientist focused on improving the lives of people with epilepsy.”

48 2021 AAN Annual Meeting

INDUSTRY THERAPEUTIC UPDATES

Join industry representatives live for unique opportunities to learn about current therapies and projects in the industry pipeline. The availability of these updates after the Annual Meeting is contingent upon regulatory requirements, so you are encouraged to attend these live events. You can also visit AAN.com/ITU for the most current schedule of Industry Therapeutic Updates.

SATURDAY • APRIL 17 Acadia Pharmaceuticals, Inc. 1:00 p.m.–2:00 p.m. ET

MONDAY • APRIL 19 Sanofi Genzyme 9:00 a.m.–10:00 a.m. ET

TUESDAY • APRIL 20 Abbott 9:00 a.m.–10:00 a.m. ET

EMD Serono, Inc. 1:00 p.m.–2:00 p.m. ET

Sunovion Pharmaceuticals, Inc. 9:00 a.m.–10:00 a.m. ET

AstraZeneca 9:00 a.m.–10:00 a.m. ET

Novartis Pharmaceuticals, Inc. 1:00 p.m.–2:00 p.m. ET

Teva CNS 9:00 a.m.–10:00 a.m. ET

UCB, Inc. 9:00 a.m.–10:00 a.m. ET

SUNDAY • APRIL 18 Biogen 9:00 a.m.–10:00 a.m. ET

Biogen 1:00 p.m.–2:00 p.m. ET

Impel NeuroPharma 1:00 p.m.–2:00 p.m. ET

Biogen 1:00 p.m.–2:00 p.m. ET

Novartis Pharmaceuticals, Inc. 1:00 p.m.–2:00 p.m. ET

Lundbeck 1:00 p.m.–2:00 p.m. ET

Viela Bio 1:00 p.m.–2:00 p.m.v

argenx 7:00 p.m.–8:00 p.m. ET

Ackea Therapeutics 7:00 p.m.–8:00 p.m. ET

Greenwich Biosciences, Inc. 7:00 p.m.–8:00 p.m. ET

Genentech, a member of the Roche group 7:00 p.m.–8:00 p.m. ET

Biohaven Pharmaceuticals 9:00 a.m.–10:00 a.m. ET Sunovion Pharmaceuticals, Inc. 9:00 a.m.–10:00 a.m. ET AbbVie, Inc. 1:00 p.m.–2:00 p.m. ET Bristol Myers Squibb 1:00 p.m.–2:00 p.m. ET Sanofi Genzyme 1:00 p.m.–2:00 p.m. ET

Janssen Neuroscience 7:00 p.m.–8:00 p.m. ET

Alexion Pharmaceuticals, Inc. 7:00 p.m.–8:00 p.m. ET Sarepta Therapeutics 7:00 p.m.–8:00 p.m. ET Genentech, a member of the Roche group 7:00 p.m.–8:00 p.m. ET

No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed.

Industry Therapeutic Updates are industry events.

nQ Medical, Inc. 7:00 p.m.–8:00 p.m. ET WEDNESDAY • APRIL 21 Viela Bio 9:00 a.m.–10:00 a.m. ET Adamas Pharmaceuticals, Inc. 1:00 p.m.–2:00 p.m. ET

COMPLETE THE SET Visit our virtual booth: www.the2musketeers.com April 17-22, 2021

INDICATION & USAGE

WARNINGS & PRECAUTIONS (CONT'D)

ONGENTYS® (opicapone) capsules is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ONGENTYS is contraindicated in patients with: • Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.

• Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

WARNINGS & PRECAUTIONS Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT) Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT, regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT. Falling Asleep During Activities of Daily Living and Somnolence Patients treated with dopaminergic medications and medications that increase levodopa exposure, including ONGENTYS, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. If a patient develops daytime sleepiness or somnolence, consider discontinuing ONGENTYS or adjusting other dopaminergic or sedating medications and advise patients to avoid driving and other potentially dangerous activities.

Hypotension/Syncope Monitor patients for hypotension and advise patients about the risk for syncope. If these adverse reactions occur, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure.

Dyskinesia ONGENTYS potentiates the effects of levodopa which may result in dyskinesia or exacerbate pre-existing dyskinesia.

Reducing the patient’s levodopa dosage or the dosage of another dopaminergic drug may reduce dyskinesia that occurs during treatment with ONGENTYS. Hallucinations and Psychosis Consider stopping ONGENTYS if hallucinations or psychotic-like behaviors occur. Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS. Impulse Control/Compulsive Disorders Patients may experience intense urges (eg, gambling, sexual, spending money, binge eating) and the inability to control them.

It is important for prescribers to specifically ask patients or their caregivers about the development of new or increased urges.

Re-evaluate the patient’s current therapies for Parkinson’s disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS. Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (elevated temperature, muscular rigidity, altered consciousness, and autonomic instability) has been reported in association with rapid dose reduction or withdrawal of drugs that increase central dopaminergic tone. There were no reports of neuroleptic malignant syndrome in ONGENTYS controlled clinical studies. When discontinuing ONGENTYS, monitor patients and consider adjustment of other dopaminergic therapies as needed.

ADVERSE REACTIONS The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, and weight decreased.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see neurocrine.com/ongentyspi for full Prescribing Information.

©2021 Neurocrine Biosciences, Inc. All Rights Reserved. CP-OPC-US-0362 04/2021 This advertisement and the information contained herein is intended for use by U.S. healthcare professionals only. Neurocrine Biosciences rights to promote, offer for sale and sell ONGENTYS is limited to the U.S. Under license from

ONGENTYSHCP.com

ONGENTYS® (opicapone) capsules, for oral use The following is a brief summary; for full Prescribing Information and Patient Information, refer to package insert.

INDICATIONS AND USAGE ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

CONTRAINDICATIONS ONGENTYS is contraindicated in patients with: • Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.

• Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

WARNINGS AND PRECAUTIONS Cardiovascular Effects with Concomitant Use of Drugs Metabolized by CatecholO-Methyltransferase (COMT) Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT (e.g., isoproterenol, epinephrine, norepinephrine, dopamine, and dobutamine), regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT.

Falling Asleep During Activities of Daily Living and Somnolence Patients treated with dopaminergic medications and medications that increase levodopa exposure, including ONGENTYS, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event.

Before initiating treatment with ONGENTYS, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with dopaminergic therapy, such as concomitant sedating medications or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), consider discontinuing ONGENTYS or adjusting other dopaminergic or sedating medications. If a decision is made to continue ONGENTYS, patients should be advised not to drive and to avoid other potentially dangerous activities.

Hypotension/Syncope In Study 1 and Study 2, hypotension (orthostatic and non-orthostatic), syncope, and presyncope occurred in 5% of patients treated with ONGENTYS 50 mg compared to 1% of patients who received placebo. Monitor patients for hypotension (orthostatic and non-orthostatic) and advise patients about the risk for syncope and presyncope. If these adverse reactions occur, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure.

Dyskinesia ONGENTYS potentiates the effects of levodopa and may cause dyskinesia or exacerbate pre-existing dyskinesia.

In controlled clinical trials (Study 1 and Study 2), dyskinesia occurred in 20% of patients treated with ONGENTYS 50 mg compared to 6% of patients who received placebo. Dyskinesia was also the most common adverse reaction leading to discontinuation of ONGENTYS. Reducing the patient’s daily levodopa dosage or the dosage of another dopaminergic drug may mitigate dyskinesia that occurs during treatment with ONGENTYS.

Hallucinations and Psychosis In Study 1 and Study 2, hallucinations (hallucinations, auditory hallucinations, visual hallucinations, mixed hallucinations) occurred in 3% of patients treated with ONGENTYS 50 mg compared to 1% of patients who received placebo. Delusions, agitation, or aggressive behavior occurred in 1% of patients treated with ONGENTYS 50 mg, and in no patient who received placebo. Consider stopping ONGENTYS if hallucinations or psychotic-like behaviors occur.

Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone. In addition, treatments for psychosis that antagonize the effects of dopaminergic medications may exacerbate the symptoms of PD.

Impulse Control/Compulsive Disorders Patients treated with ONGENTYS can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more dopaminergic therapies that increase central dopaminergic tone. In some cases, these urges were reported to have stopped when the dose was reduced, or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, or other urges while being treated with ONGENTYS. In Study 1 and Study 2, impulse control disorders occurred in 1% of patients treated with ONGENTYS 50 mg, and in no patient who received placebo. Re-evaluate the patient’s current therapy(ies) for Parkinson’s disease and consider stopping ONGENTYS if a patient develops such urges while taking ONGENTYS. Use with caution in Parkinson’s patients with suspected or diagnosed dopamine dysregulation syndrome.

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone. In the controlled clinical studies of ONGENTYS, patients discontinued ONGENTYS treatment without dose tapering or gradual withdrawal. There were no reports of neuroleptic malignant syndrome in ONGENTYS controlled clinical studies. When discontinuing ONGENTYS, monitor patients and consider adjustment of other dopaminergic therapies as needed.

ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: • Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-OMethyltransferase (COMT) • Falling Asleep During Activities of Daily Living and Somnolence • Hypotension/Syncope • Dyskinesia • Hallucinations and Psychosis • Impulse Control/Compulsive Disorders • Withdrawal-Emergent Hyperpyrexia and Confusion

Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ONGENTYS was evaluated in 265 patients with Parkinson’s disease (PD) in two 14-15 week placebo- and active-controlled (Study 1) or placebo-controlled (Study 2) studies. All patients were taking a stable dose of levodopa and a DOPA decarboxylase inhibitor, alone or in combination with other PD medications. In Study 1 and Study 2, the mean age of patients was 63.6 years, 59% of patients were male, and 89% of patients were Caucasian. At baseline, the mean duration of PD was 7.6 years.

Adverse Reactions Leading to Discontinuation of Treatment In Study 1 and Study 2, a total of 8% of ONGENTYS 50 mg-treated patients and 6% of patients who received placebo discontinued due to adverse events. The most common adverse reaction leading to discontinuation was dyskinesia, reported in 3% of ONGENTYS 50 mg-treated patients and 0.4% of patients who received placebo.

Common Adverse Reactions Adverse reactions that occurred in the pooled studies at an incidence of at least 2% and greater than placebo are presented in Table 1. The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/ syncope, and weight decreased.

Table 1: Adverse Reactions with an Incidence of at Least 2% in Patients Treated with ONGENTYS and Greater than on Placebo, in Pooled Study 1 and Study 2 Adverse Reactions

1 2

ONGENTYS 50 mg N=265 %

Placebo N=257 %

Nervous system disorders Dyskinesia Dizziness

20 3

6 1

Gastrointestinal disorders Constipation Dry mouth

6 3

2 1

Psychiatric disorders Hallucination1 Insomnia

3 3

1 2

Investigations Blood creatine kinase increased Weight decreased

5 4

2 0

Vascular disorders Hypotension/syncope 2 Hypertension

5 3

1 2

Includes hallucinations, hallucinations visual, hallucinations auditory, and hallucinations mixed Includes hypotension, orthostatic hypotension, syncope, and presyncope

DRUG INTERACTIONS Non-Selective Monoamine Oxidase (MAO) Inhibitors Both ONGENTYS and non-selective MAO inhibitors (e.g., phenelzine, isocarboxazid, and tranylcypromine) inhibit catecholamine metabolism, leading to increased levels of catecholamines.

Concomitant use may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure.

Concomitant use of ONGENTYS with non-selective MAO inhibitors is contraindicated. Selective MAO-B inhibitors can be used concomitantly with ONGENTYS.

Effect of ONGENTYS on Other Drugs Drugs Metabolized by Catechol-O-Methyltransferase (COMT) Concomitant use of ONGENTYS with drugs metabolized by COMT may affect the pharmacokinetics of those drugs, which may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure. Drugs known to be metabolized by COMT should be administered with caution. Monitor for changes in heart rate, rhythm, and blood pressure in patients concomitantly treated with ONGENTYS and drugs metabolized by COMT.

OVERDOSAGE No specific antidotes for ONGENTYS are known. As a general measure, removal of ONGENTYS by gastric lavage and/or inactivation by administering activated charcoal should be considered. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an over-exposure occurs, call your poison control center at 1-800-222-1222 or www.poison.org.

For further information on ONGENTYS, call 1-833-ONGENTYS (833-664-3689) or visit www.ongentys.com Distributed by: Neurocrine Biosciences, Inc., San Diego, CA 92130 Under license from BIAL-Portela & Ca, S.A. ONGENTYS is a registered trademark of BIAL-Portela & Ca, S.A. Rx Only CP-OPC-US-0111 09/2020

EXPERIENTIAL LEARNING AREAS Experiential Learning Areas (ELAs) are short, engaging talks and presentations designed to help you advance intellectually, personally, and professionally.

Explore six areas that will spark your imagination and help you learn in fresh ways.

From conversation corners to talks with physicians and AAN staff, you'll find plenty of opportunities to engage with speakers. Learn more about each area and see complete talk lineups at AAN.com/ELA.

EXPERIENTIAL LEARNING AREAS

ACADEMIC NEUROLOGY is…

Timely. Engaging. Personalized.

This is a brand-new ELA exclusively focused on academic neurology.

If you are in any position in an academic neurology department, this is a one-stop shop to explore and learn about everything related to academic neurology.

Highlighted talks in this area include:

Academic Neurology: What Is the AAN Doing to Help Academic Neurology Saturday, April 17, 9:00 a.m.–9:30 a.m. ET Ralph L. Sacco, MD, MS, FAHA, FAAN Come hear what the AAN is doing for academic neurology and let us know what else we can do to help you.

Different Pathways to Becoming a Chair Saturday, April 17, 4:00 p.m.–4:30 p.m. ET Frances E. Jensen, MD, FAAN; Cathy A. Sila, MD, FAAN; and Robin L. Brey, MD, FAAN This panel will discuss essential responsibilities and traits individuals need to address while considering a future as a chair.

Turning ”Diversity Tax” into Currency in Neurology Sunday, April 18, 9:00 a.m.–9:30 a.m. ET Roy H. Hamilton, MD, MS, FAAN In this talk, we recognize the burden that the diversity tax places on certain populations of practicing neurologists and trainees; discuss strategies for finding the right balance between promoting diversity-related activities and dedicating oneself to traditional career goals; and present practical strategies for translating diversity-related efforts into activities that are considered meritorious for career development in neurology.

Sharing of Best Practices for Division Chiefs in an Academic Neurology Department Wednesday, April 21, 9:00 a.m.–9:30 a.m. ET Brenda Banwell, MD, FAAN This program is for new and current Neurology Division Chiefs to learn best practices in an approach where the speakers talk about things that went great and things we would not do again.

54 2021 AAN Annual Meeting

ADVANCING LEADERSHIP IN NEUROLOGY is…

Transformative. Career Growth.

Awareness-building.

This brand-new ELA is the primary place at the Annual Meeting to learn about core leadership concepts that you can use to advance your career presented alongside timely issues relating to Inclusion, Diversity, Equity, Anti-racism, and Social Justice. If you are curious to learn more about leadership concepts and want to increase your self-awareness and knowledge, this is the ELA for you. Also, be sure to stop by to take self-administered bias tests to learn where you currently stand, and what you can learn more about. This area will also include opportunities throughout the week to engage directly with Leadership Program alumni on a variety of exciting topics.

Highlighted talks in this area include:

This live panel discussion features a presentation by expert consultant Laraine Kaminsky, who specializes in developing inclusive leaders.

Following the panel discussion, join us for interactive breakout sessions and an open panel discussion with Academy Board Members Dr. Flippen, Dr. Miyasaki, and AAN Equity, Diversity, and Inclusion Joint Coordinating Council Chair Dr. McClean.

Health Care Disparities in Populations Tuesday, April 20, 6:00 p.m.–6:30 p.m. ET Alejandro Vargas, MD, and Sharon Lewis, MD Come participate in an open forum for discussion on tackling health care disparities and constructive ways to promote awareness.

Additionally, this area will host a series of three talks on crucial leadership concepts, led by professional leadership consultants:

Emotional Intelligence and Leadership Saturday, April 17, 2:00 p.m.–2:30 p.m. ET Joanne Smikle, PhD Find out why emotional intelligence is the factor that can make or break your career as a leader.

Negotiation Techniques and Tools Monday, April 19, 6:00 p.m.–6:30 p.m. ET Selena Rezvani Negotiation remains a key foundational skill for any leader.

Navigating Conflict in a Virtual World Thursday, April 22, 4:00 p.m.–4:30 p.m. ET Barbara L. Hoese With the change to a virtual model over the last year, how do you handle when conflicts arise?

AAN.com/21AM

55

EXPERIENTIAL LEARNING AREAS

Blind Spots: The Impact of Conscious and Unconscious Biases Sunday, April 18, 4:00 p.m.–5:30 p.m. ET Charles C. Flippen, II, MD, FAAN; Jeffrey C. McClean, II, MD, FAAN; Laraine Kaminsky; and Janis Miyasaki, MD, FAAN

EXPERIENTIAL LEARNING AREAS CAREERS IN NEUROLOGY is…

Resourceful. Innovative. Diverse.

This ELA is a great opportunity to explore and navigate your career by taking in the variety of offerings covering topics in research and careers.

EXPERIENTIAL LEARNING AREAS

Highlighted talks in this area include:

What Should Applicants Look for in a Program?

Saturday, April 17, 1:00 p.m.–1:30 p.m. ET Peter Hannon, MD, and Adam De Havenon, MD

K Is for Career Development Tuesday, April 20, 9:00 a.m.–9:30 a.m. ET Holly E. Hinson, MD, MCR, FAAN

Drawing on years of program director experience in neurology residency and fellowship, the presenters' focus will be on what makes a training program the right fit for an applicant, and not the other way around.

This session will cover the different types of Ks, how a K differs from other Career Development Awards, the sections of the application, and hints to get started. The talk will end with time for attendee questions.

Are You My Mentor?: How to Select a Good Mentor for Your Research Program Sunday, April 18, 9:00 a.m.–9:30 a.m. ET Deborah Hall, MD, PhD, FAAN

How the Neuroscience of Bias Changed My Career Thursday, April 22, 9:00 a.m.–9:30 a.m. ET Jose H. Posas, MD, FAAN

Back by popular demand, come to this talk to learn how to select a good mentor for your research.

In this talk, faculty will delve into how they were able to channel anger and outrage at health care disparities they were seeing around them into actionable items on a rising agenda that has helped them help their patients, their community, and their future colleagues.

A Career in General Neurology: Knowing Everything About Everything Monday, April 19, 9:00 a.m.–9:30 a.m. ET Kirk Roberts, MD, FAAN This discussion will focus on the challenges and rewards of general neurology and ask for audience participation on how to succeed in this field and how to maintain trainee interest in general neurology in this era of ever-increasing subspecialization.

56 2021 AAN Annual Meeting

HEADTALKS is…

Creative. Unique. Compelling.

This popular ELA is back! HeadTalks are an incredibly unique form of education at the AAN. The focus of HeadTalks is on having amazing speakers connect with their audience on a topic that you won’t hear anywhere else. This ELA is less focused on slides and more on interactive and storytelling sessions that serve both to educate us but also to entertain and even inspire us. The beauty of HeadTalks is that you could be a well-seasoned renowned neurologist or a non-neurologist and find incredible value from the session. ”HeadTalks are often what most attendees recall about the meeting.

It’s that great!”

Joseph Sirven, MD, FAAN

Beyond the White Coat: Who We are, Where We Live, What We Love Saturday, April 17, 3:00 p.m.–3:35 p.m. ET Ann H. Tilton, MD, FAAN; Ralph L. Sacco, MD, MS, FAHA, FAAN; Cynthia L. Comella, MD, FAAN; Nina F. Schor, MD, PhD, FAAN; and Joseph F. Drazkowski, MD, FAAN Have you ever wanted to learn more about what your neurology colleagues do in their free time? This interesting new session will feature homes, hobbies, and unique talents of a variety of neurologists.

Neuro-oncology Around the World— Global Perspective on Brain Cancer Patient Care Monday, April 19, 3:00 p.m.–3:35 p.m. ET Maciej M. Mrugala, MD, PhD, MPH, FAAN; Agnieszka Slowik; Hui K. Gan; Alejandro Zavala Reina; and Kathy Oliver

The Neurology of Wine Tasting Tuesday, April 20, 5:00 p.m.–5:35 p.m. ET Jaime R. Lopez, MD We will review what happens, physiologically and emotionally, when we taste wine. We encourage you to grab a glass or two of wine, if two glasses, then two different wines, and join me and our guest sommelier, Mr. Youbirt Aissa, in an interactive wine tasting.

Neurology Trivia: Localize the Lesion Wednesday, April 21, 1:00 p.m.–2:00 p.m. ET Luis F. Torres, MD This is an interactive game show where peers compete against each other attempting to answer questions related to common and uncommon neurologic conditions.

During this panel discussion, speakers will introduce neuro-oncology as a specialty, discuss the field and how it developed over the years, and then end with a question and answer session.

AAN.com/21AM

57

EXPERIENTIAL LEARNING AREAS

Highlighted talks in this area include:

EXPERIENTIAL LEARNING AREAS LIVE WELL is…

Awareness-building. Honest. Supportive.

Taking care of your patients begins with taking care of yourself.

Since focusing on wellness is vital for everyone, the Live Well ELA will offer resources for everyone with particular focus on the practicing neurologist or resident who is juggling professional commitments with life outside of practice. Those who are currently experiencing stress and looking for solutions that have worked for other like-minded professionals may especially benefit from visiting the Live Well ELA. Stop by for daily yoga sessions and meditation, brain games, take a mini escape with the aquarium cam, and to tap into a wealth of wellness resources throughout the meeting.

EXPERIENTIAL LEARNING AREAS

Highlighted talks in this area include:

Family Caring and Parenting Sunday, April 18, 9:00 a.m.–9:30 a.m. ET Amtul Farheen, MD, FAAN; Nancy Hammond, MD; and Paul G. Mathew, MD, FAAN

Exercise and Physical Activity in the Time of COVID-19 Tuesday, April 20, 5:00 p.m.–5:30 p.m. ET Ann Marie Collier, MD

This panel discussion will address unique challenges neurologists face while being both doctors and caring for children, parents, or family members.

This talk will address the impact of isolation during the current COVID-19 pandemic on our health and discuss ways to incorporate healthy habits of moving and exercising to boost one's sense of wellness and overall health.

What About Wellness for Residents and Fellows?

Tuesday, April 20, 3:00 p.m.–3:30 p.m. ET Aimee Aoi Sato, MD Addressing organizational, systemic, and cultural factors of wellness are crucial, but takes time and are unfortunately often not in the control of residents. We will focus on concrete things that you, as the resident or fellow, can do to increase your well-being.

58 2021 AAN Annual Meeting

Your Career Environment Wednesday, April 21, 9:00 a.m.–9:30 a.m. ET Cormac A. O'Donovan, MD This talk will approach the work environment within the practice of neurology, and techniques that can be used to increase one’s sense of wellbeing within their workplace–wherever that may be!

PIONEERING PRACTICE, POLICY, AND PERFORMANCE: STAYING AHEAD OF CHANGE is…

Innovative. Empowering. Engaging.

Covering topics often left out of traditional courses, this ELA fills the gap for attendees interested in learning how to improve their practice and increase revenue by adopting cutting-edge technology, maximizing the potential of their care team, and incorporating advocacy issues. Attendees from any practice setting curious about navigating the changing landscape of medicine should attend for practice management solutions, paths to advocacy to lesson your burden, or empowerment to adopt technology to improve the lives of providers and patients.

Highlighted talks in this area include:

Neurology Networking & Advocacy Through Social Media Monday, April 19, 2:00 p.m.–3:00 p.m. ET Kara Stavros, MD; Ima M. Ebong, MD; Justine Ker; Jeff Kraakevik, MD; Kathrin LaFaver, MD, FAAN; and Aarti Sarwal, MD, FAAN

This live, interactive talk includes perspectives from several neurologists on how their areas of expertise collide with the gaming world.

This will be a panelist-based discussion and Q&A on how social media can be used to foster community and increase visibility for neurologycentered topics, as well as motivate current and inspire future neurologists. This talk is also live and interactive—learn how to advocate for patients and neurology and enhance your social media presence, in real time!

Moving the Needle Forward Together: An Opportunity to Dialogue with Physician Leaders from Epic and Cerner Sunday, April 18, 2:00 p.m.–3:00 p.m. ET Allison L. Weathers, MD, FAAN; Jamie Grenier; Jeffrey Wall, MD; Kelly Mundth, RN, MSN-Ed; and Dave Little, MD Join this talk for a moderated panel where you will hear directly from the physician leaders of the two major electronic health record vendors used by most neurologists. Most importantly, participants will be able to voice their ideas for optimizations and improvements.

Talks for Trainees: Understanding Patients as Consumers Tuesday, April 20, 9:00 a.m.–10:00 a.m. ET Allison L. Weathers, MD, FAAN; Marsha Smith, MD, FAAN; and Michael Anthony Leander Johnson, MD

This talk explores medical care delivery through the perspectives of patients as customers.

Through interactive case-based scenarios, we will Meet Your Practice Support Network: Ask explore several potential influences on health care Us Anything About Managing Your Practice consumer perceptions and discuss how providers can prepare for these and avoid pitfalls.

Sunday, April 18, 6:00 p.m.–7:00 p.m. ET Michael E. Markowski, DO, FAAN; Gurdesh Bedi, MD, FAAN; and Marcia Dover, MD

2021 Coding Odyssey Tuesday, April 20, 2:00 p.m.–3:00 p.m. ET Learn about the AAN’s resources for solo and small Brian T. Cabaniss, MD, and Meghan Ashley practitioners and be sure to bring questions for the Ward, MD panel.

Through interactive case examples, faculty will guide the audience through the nuances of billing based on time and medical decision making (MDM) with this new code set. Each case will be followed by an open discussion period to address any questions members have based on experiences in their own practices.

AAN.com/21AM

59

EXPERIENTIAL LEARNING AREAS

The Neurology of Video Games Saturday, April 17, 2:00 p.m.–3:00 p.m. ET Daniel Joseph Ackerman, MD; Jose H. Posas, MD, FAAN; Delia Bakeman, MD; Julia Esther Staisch, MD; Priscilla Chee, MD; and Alissa A. Chitlangia, MD

NAVIGATING THROUGHOUT

THEIR RELAPSING

MS JOURNEY

VISIT US AT THE 2021 VIRTUAL AAN ANNUAL MEETING TO LEARN ABOUT BIOGEN’S TREATMENT OPTIONS FOR YOUR PATIENTS LIVING WITH RELAPSING MULTIPLE SCLEROSIS (MS).

VISIT US APRIL 17-22 AT NEUROLOGY.BIOGENVIRTUAL.COM/MS/HCP

©2021 Biogen. All rights reserved. | FCH-US-6997 03/21

BECAUSE NO TWO PATIENTS ARE THE SAME

VIRTUAL PLATFORM GUIDE The following guide will help you get started at the virtual 2021 AAN Annual Meeting. Learn how to access and navigate the virtual platform. Use your computer and Google Chrome as your browser for the best experience.

How to Access Logging In 1. Ensure you are registered for the meeting. If you need to register, visit AAN.com/21AM. 2. Starting April 15, 2021, visit the virtual platform login page at AAN.com/VirtualAM (View the platform on your computer with Google Chrome as your browser for the best experience).

3. Type your email or 6-digit member ID and password (this is the same information you use to access AAN.com).

4. Click ”Log in.”

5. Trouble logging in? Check your email to confirm your credentials or email registration@aan.com.

How to Enter the Platform • Click Enter on the home screen—the brain—to enter the virtual platform lobby.

• Once in the lobby, watch the daily video to hear about some of the can't- miss items, then begin exploring the platform.

• Need help? Use the chat icon on the lower right-hand side of the screen to access tech support. To ensure you have the best virtual experience, we have real people with real-time answers who will be available to assist you any time during the virtual meeting.

AAN.com/21AM

61

VIRTUAL PLATFORM GUIDE

Virtual platform lobby design is current as of March 19, 2021, and is subject to change.

Navigating the Lobby In the lobby, you'll see different areas and various auditoriums, each featuring a variety of program types you can explore. Clicking on them will take you to further information and features, including: Daily Welcome Video: Get a preview of what’s upcoming for the day and can’tmiss highlights!

Today's Education Courses: Click to view education programs using one or more teaching methods, including didactic, interactive, and case-based. Once you enter this auditorium, use tabs to navigate by courses happening on the day you are searching or future dates. Personalize your meeting experience by selecting "Add to My Agenda" for any education courses you wish to add to your schedule.

Today's Scientific Sessions: Click to view a group of abstracts covering a similar topic presented in an oral format with two opportunities for interactive audience Q&A. In this auditorium, you'll also find Neuroscience in the Clinic Sessions, Invited Science Sessions, and the Sunday, April 18, Emerging Science Session. Once you enter this auditorium, use tabs to navigate by science happening on the day you are searching or future dates. Personalize your meeting experience by selecting "Add to My Agenda" for any science you wish to add to your schedule.

Today's Plenary Sessions: From the hottest and timeliest science around COVID-19 to a year-end review of top findings, this year’s plenary sessions will feature an impressive lineup of researchers showcasing their very latest breakthroughs in neuroscience. Once you enter this auditorium, use tabs to navigate by plenary sessions happening on the day you are searching or future dates. Personalize your meeting experience by selecting "Add to My Agenda" for any plenary session you wish to add to your schedule. Learn more on page 23.

62 2021 AAN Annual Meeting

Experiential Learning Areas: Check out short, engaging talks and presentations designed to help you advance intellectually, personally, and professionally. Learn more on page 54.

Posters: Visit this area throughout the meeting to ask abstract authors questions during dedicated live video office hours and/or via other interactive chat features.

AAN Rewind: View programs that have already happened on demand within approximately 24 hours of the originally scheduled time. You can rewind and revisit your favorite Education Courses, Scientific Sessions, Plenary Sessions, and Experiential Learning Area Talks on the virtual platform through May 23, 2021.

Exhibits: Visit the engaging and dynamic virtual exhibit hall. Explore the latest products available to help improve your service to patients in the exhibit hall, which will be open throughout the conference. The virtual conference platform allows for attendees to have engaging conversations with industry representatives.

Industry Therapeutic Updates: Join live presentations to hear directly from industry representatives and learn more about therapies available to patients.

Learn more on page 49.

Networking/Entertainment Hub: One location to find all of the meaningful networking and engagement opportunities you've been craving. With three opportunities per day to join casual video conversations with other attendees on different themes and topics, a photo booth, leaderboard, World Map to see who is at the meeting, and more, we've got virtual networking covered. Learn about all the opportunities on page 19.

Awards Theater: Looking for the best and brightest in the field of neurology?

Stop by the Awards Theater to view the top leaders in science, including your colleagues from around the globe and in a variety of career stages. Access videos and download take-home tools and resources. Learn more on page 28.

AAN Showcase: Learn more about what the AAN has to offer through chat or one-on-one video with AAN staff about various products, interests, and services. Learn more on page 26.

Information: Access technical support about the virtual platform and get answers to all of your questions about the American Academy of Neurology from real people with real-time answers. You can find technical support in the same lower right-hand corner of the screen on every page of the virtual platform.

Main Menu: Use this navigation bar to access many of the same elements visible in the lobby. The Main Menu will also offer convenient direct access to claim CME, evening entertainment, programming for trainees, the FAQ, as well as "My Items," which includes any downloaded items from the AAN Showcase or exhibitors and your direct messages with other attendees.

AAN.com/21AM

63

MOBILE APP GUIDE

Download the AAN Conferences mobile app in the App Store or Google Play.

Log in using your email or 6-digit Member ID and password (this is the same information you use to access AAN.com).

Add your interests to your profile to get tailored program recommendations Build your personalized agenda and get reminders 5 minutes before your scheduled sessions Watch select sessions live (recommended for tablets only for the best viewing experience) CME

Access program materials, submit your program evaluations, and claim CME Turn on push notifications to get helpful reminders and tips throughout the Annual Meeting Filter by specially curated program tracks to help find sessions most relevant to you Discover Annual Meeting highlights and can’t-miss events

Read what’s being said at the Annual Meeting and join the conversation using #AANAM on Facebook, Twitter, Instagram, LinkedIn 64 2021and AAN Annual Meeting

Health Care Equity Symposium Quality Health Care for All

Monday, April 19, 2021, 1:00 p.m.–3:00 p.m. ET In today’s world, the reality is that access to quality health care varies greatly depending on race, gender, socioeconomic status, and sexual identity. Join us at the Health Care Equity Symposium as we explore ways we can eliminate the disparity gap.

This symposium will include the Cheryl A. Jay Keynote Lecture, presented by Joseph R. Betancourt, MD, MPH, followed by a panel discussion and live Q&A session, featuring: Richard T. Benson, MD, PhD ■ National Institute of Neurological Disorders and Stroke NIH Office of Global Health and Health Disparities

Nicte I. Mejia, MD, MPH, FAAN ■ Harvard Medical School and Massachusetts

Nicole Rosendale, MD ■ University of California, San Francisco Jeffrey C. McClean II, MD, FAAN, Lt Col ■ USAF, MC BAMC Department Of Medicine

General Hospital

Learn more: AAN.com/21AM

Cheryl A. Jay Keynote Lecture Dr. Cheryl A. Jay (1960 – 2019) was a gifted clinical neurologist who was passionate about social justice in health care and serving the underprivileged.

STRUCTURAL EQUITY: LESSONS FROM 2020 Joseph R. Betancourt, MD, MPH Expert in health policy, health care disparities, diversity, and cross-cultural medicine.

■ Vice President, Chief Equity and Inclusion Officer, Massachusetts General Hospital ■ Founder, Senior Advisor and Faculty, The Disparities Solutions Center ■ Faculty, The Mongan Institute ■ Associate Professor of Medicine, Harvard Medical School

201 Chicago Avenue Minneapolis, MN 55415

AAN Excellence— Delivered Unconventionally Register now for the world’s premier neurology meeting— in a new, fully virtual format!

AAN.com/21AM April 17– April 22